// {
//   "studies": [
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT05013879",
//           "orgStudyIdInfo": {
//             "id": "2021-13203"
//           },
//           "organization": {
//             "fullName": "Montefiore Medical Center",
//             "class": "OTHER"
//           },
//           "briefTitle": "Kinesiotape for Edema After Bilateral Total Knee Arthroplasty",
//           "officialTitle": "Effect of Kinesiotaping on Edema Management, Pain and Function on Patients With Bilateral Total Knee Arthroplasty"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2024-02",
//           "overallStatus": "COMPLETED",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2021-10-18",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2023-11-24",
//             "type": "ACTUAL"
//           },
//           "completionDateStruct": {
//             "date": "2023-11-24",
//             "type": "ACTUAL"
//           },
//           "studyFirstSubmitDate": "2021-08-02",
//           "studyFirstSubmitQcDate": "2021-08-18",
//           "studyFirstPostDateStruct": {
//             "date": "2021-08-19",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2024-02-21",
//           "lastUpdatePostDateStruct": {
//             "date": "2024-02-23",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "SPONSOR"
//           },
//           "leadSponsor": {
//             "name": "Montefiore Medical Center",
//             "class": "OTHER"
//           },
//           "collaborators": [
//             {
//               "name": "Burke Rehabilitation Hospital",
//               "class": "OTHER"
//             }
//           ]
//         },
//         "oversightModule": {
//           "oversightHasDmc": false,
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": false
//         },
//         "descriptionModule": {
//           "briefSummary": "The purpose of this study is to determine if kinesiotaping for edema management will decrease post-operative edema in patients with bilateral total knee arthroplasty. The leg receiving kinesiotaping during inpatient rehabilitation may have decreased edema and pain and improved movement and function when compared to the leg not receiving kinesiotape.",
//           "detailedDescription": "After being informed about the study and potential risk, all patients undergoing inpatient rehabilitation after bilateral total knee arthroplasty will have Kinesio(R)Tape applied to one randomly selected leg while the other leg serves as a control. Measurement of bilateral leg circumference, knee range of motion, numerical rating scale for pain, and selected questions from the Knee Injury and Osteoarthritis Outcome Score will occur at regular intervals throughout the rehabilitation stay. Patients will receive standard rehabilitation."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Arthroplasty Complications",
//             "Arthroplasty, Replacement, Knee"
//           ],
//           "keywords": [
//             "edema",
//             "arthroplasty, knee, bilateral",
//             "kinesiotaping"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "NA"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "SINGLE_GROUP",
//             "interventionModelDescription": "Repeated measures with two within-subjects factors: time and taped/untaped leg",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "NONE"
//             }
//           },
//           "enrollmentInfo": {
//             "count": 65,
//             "type": "ACTUAL"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "Kinesiotape leg plus standard rehabilitation",
//               "type": "EXPERIMENTAL",
//               "description": "Kinesio(R)Tape for edema management applied to a randomly selected lower extremity plus standard inpatient rehabilitation after bilateral total knee arthroplasty",
//               "interventionNames": [
//                 "Device: Kinesio(R)Tape for edema control"
//               ]
//             },
//             {
//               "label": "Control leg with standard rehabilitation alone",
//               "type": "NO_INTERVENTION",
//               "description": "Control leg receiving standard inpatient rehabilitation alone."
//             }
//           ],
//           "interventions": [
//             {
//               "type": "DEVICE",
//               "name": "Kinesio(R)Tape for edema control",
//               "description": "Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.",
//               "armGroupLabels": [
//                 "Kinesiotape leg plus standard rehabilitation"
//               ],
//               "otherNames": [
//                 "kinesiotaping or kinesiological taping"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Change from baseline and during 1-2-day time intervals of circumferences of both knees and lower extremities",
//               "description": "Bilateral circumferences, in centimeters, at the following points: 10 cm above the superior pole of the patella; middle of the knee joint; calf circumference at the broadest part of the calf and at 3 inches below the fibular head landmark; figure of eight method for foot and ankle circumference - a measurement from the lateral malleolus to the navicular tuberosity, under the plantar aspect of the foot towards the tuberosity of the fifth metatarsal, around to the medial malleolus, and posterior to the leg to return to the lateral malleolus.",
//               "timeFrame": "During inpatient rehabilitation stay for each subject: at baseline (day 0), day 1, day 2, and every other day until day 8"
//             }
//           ],
//           "secondaryOutcomes": [
//             {
//               "measure": "Change from baseline and day-to-day changes of bilateral knee pain on numerical pain rating scale",
//               "description": "Patient self-report: Pain rating for each leg on a integer scale of 0 (no pain) to 10 (worst pain imaginable)",
//               "timeFrame": "During inpatient rehabilitation stay for each subject: at baseline (day 0), day 1, day 2, and every other day until day 8"
//             },
//             {
//               "measure": "Change from baseline and during 1-2-day time intervals for bilateral knee range of motion",
//               "description": "Physical therapist's measurement of active and active assistive knee range of motion (degrees) for flexion and extension using a standard goniometer",
//               "timeFrame": "During inpatient rehabilitation stay for each subject: at baseline (day 0), day 1, day 2, and every other day until day 8"
//             },
//             {
//               "measure": "Change from baseline to Day 4 to Discharge Day for selected parts of the Knee Injury and Osteoarthritis Outcome Score (KOOS) self-report",
//               "description": "Patient self-report using the KOOS sections relating to pain, stiffness, activities of daily living",
//               "timeFrame": "At start of study, 4 days after start of study, and day 8"
//             },
//             {
//               "measure": "Change from baseline and during 1-2-day time intervals for Timed Up-and-Go Test",
//               "description": "Time (sec) to rise from a seated position, walk 10 m, turn, walk back to seat, and sit down. Patient will use appropriate assistive device and have appropriate guarding by a physical therapist.",
//               "timeFrame": "During inpatient rehabilitation stay for each subject: at baseline (day 0), day 1, day 2, and every other day until day 8"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n* admitted to Burke Rehabilitation Hospital for inpatient rehabilitation within 5 days after same-day or staged bilateral total knee arthroplasty;\n* 50-85 years of age;\n* able to read and understand English or a hospital-provided translator when consenting for the study;\n* free from contraindications for kinesiotaping (see below); and,\n* able to tolerate an active rehabilitation program.\n\nExclusion Criteria:\n\n* stage III or IV heart failure, stage III or IV renal failure;\n* fragile, very hairy or sensitive skin;\n* anesthesia or paraesthesia of any area of the lower extremity, except the surgical sites\n* active skin rashes or infections or skin lesions in the lower extremity;\n* prior history of allergic reactions to skin taping, bandaids, surgical tape; athletic tape or other skin-adhering electrode adhesives;\n* prior history of lower extremity lymphedema;3\n* prior history of lower extremity venous or arterial disease;\n* post-operative complications in the surgical sites;4\n* partial joint arthroplasty or revision arthroplasty of one or both knees;1,5\n* inability to give informed consent offered in English or through a hospital-provided translator\n* age less than 50 years or over 85 years;\n* inability to tolerate an active rehabilitation program.",
//           "healthyVolunteers": false,
//           "sex": "ALL",
//           "minimumAge": "50 Years",
//           "maximumAge": "85 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "overallOfficials": [
//             {
//               "name": "Suzanne Babyar, PT, PhD",
//               "affiliation": "Burke Rehabilitation Hospital",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "Burke Rehabilitation Hospital",
//               "city": "White Plains",
//               "state": "New York",
//               "zip": "10605",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 41.03399,
//                 "lon": -73.76291
//               }
//             }
//           ]
//         },
//         "referencesModule": {
//           "references": [
//             {
//               "pmid": "32459670",
//               "type": "BACKGROUND",
//               "citation": "Tornatore L, De Luca ML, Ciccarello M, Benedetti MG. Effects of combining manual lymphatic drainage and Kinesiotaping on pain, edema, and range of motion in patients with total knee replacement: a randomized clinical trial. Int J Rehabil Res. 2020 Sep;43(3):240-246. doi: 10.1097/MRR.0000000000000417."
//             },
//             {
//               "type": "BACKGROUND",
//               "citation": "Guney Deniz H, Kinikli GI, Onal S, Sevinc C, Caglar O, Yuksei I. Comparison of Kinesio Tape application and manual lymphatic drainage on lower extremity oedema and functions after total knee arthroplasty. [Abstract]. Ann Rheum Dis. 2018; 77: 1791."
//             },
//             {
//               "pmid": "24819349",
//               "type": "BACKGROUND",
//               "citation": "Donec V, Krisciunas A. The effectiveness of Kinesio Taping(R) after total knee replacement in early postoperative rehabilitation period. A randomized controlled trial. Eur J Phys Rehabil Med. 2014 Aug;50(4):363-71. Epub 2014 May 13."
//             },
//             {
//               "type": "BACKGROUND",
//               "citation": "Sulman M, Riaz S, Khan RR, Faisal Z, Rajput R, Noor M. Effectiveness of Kinesio Taping on pain and function after total knee arthroplasty. Pak J Med Health Sci. 2020;14:1267-1270."
//             },
//             {
//               "pmid": "30208939",
//               "type": "BACKGROUND",
//               "citation": "Oktas B, Vergili O. The effect of intensive exercise program and kinesiotaping following total knee arthroplasty on functional recovery of patients. J Orthop Surg Res. 2018 Sep 12;13(1):233. doi: 10.1186/s13018-018-0924-9."
//             },
//             {
//               "pmid": "26223312",
//               "type": "BACKGROUND",
//               "citation": "Alghadir A, Anwer S, Brismee JM. The reliability and minimal detectable change of Timed Up and Go test in individuals with grade 1-3 knee osteoarthritis. BMC Musculoskelet Disord. 2015 Jul 30;16:174. doi: 10.1186/s12891-015-0637-8."
//             },
//             {
//               "pmid": "30341552",
//               "type": "BACKGROUND",
//               "citation": "Hancock GE, Hepworth T, Wembridge K. Accuracy and reliability of knee goniometry methods. J Exp Orthop. 2018 Oct 19;5(1):46. doi: 10.1186/s40634-018-0161-5."
//             },
//             {
//               "pmid": "23948839",
//               "type": "BACKGROUND",
//               "citation": "Unver B, Ertekin O, Karatosun V. Pain, fear of falling and stair climbing ability in patients with knee osteoarthritis before and after knee replacement: 6 month follow-up study. J Back Musculoskelet Rehabil. 2014;27(1):77-84. doi: 10.3233/BMR-130422."
//             },
//             {
//               "pmid": "29075347",
//               "type": "BACKGROUND",
//               "citation": "Bakar Y, Ozdemir OC, Sevim S, Duygu E, Tugral A, Surmeli M. Intra-observer and inter-observer reliability of leg circumference measurement among six observers: a single blinded randomized trial. J Med Life. 2017 Jul-Sep;10(3):176-181."
//             },
//             {
//               "pmid": "22840304",
//               "type": "BACKGROUND",
//               "citation": "Collins NJ, Roos EM. Patient-reported outcomes for total hip and knee arthroplasty: commonly used instruments and attributes of a \"good\" measure. Clin Geriatr Med. 2012 Aug;28(3):367-94. doi: 10.1016/j.cger.2012.05.007. Epub 2012 Jun 22."
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "NO"
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D004487",
//               "term": "Edema"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M13066",
//               "name": "Pain",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7657",
//               "name": "Edema",
//               "asFound": "Edema",
//               "relevance": "HIGH"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC23",
//               "name": "Symptoms and General Pathology"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT00517179",
//           "orgStudyIdInfo": {
//             "id": "CRE-2006.017-T"
//           },
//           "secondaryIdInfos": [
//             {
//               "id": "HARECCTR0500057"
//             }
//           ],
//           "organization": {
//             "fullName": "Hospital Authority, Hong Kong",
//             "class": "OTHER_GOV"
//           },
//           "briefTitle": "Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS",
//           "officialTitle": "Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2011-06",
//           "overallStatus": "COMPLETED",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2006-04"
//           },
//           "completionDateStruct": {
//             "date": "2007-05",
//             "type": "ACTUAL"
//           },
//           "studyFirstSubmitDate": "2007-08-15",
//           "studyFirstSubmitQcDate": "2007-08-15",
//           "studyFirstPostDateStruct": {
//             "date": "2007-08-16",
//             "type": "ESTIMATED"
//           },
//           "lastUpdateSubmitDate": "2011-06-14",
//           "lastUpdatePostDateStruct": {
//             "date": "2011-06-16",
//             "type": "ESTIMATED"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "leadSponsor": {
//             "name": "Hospital Authority, Hong Kong",
//             "class": "OTHER_GOV"
//           }
//         },
//         "descriptionModule": {
//           "briefSummary": "The purpose of this study is to investigate the interaction between doxazosin GITS and vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with both ED and BPH."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Prostatic Hyperplasia",
//             "Impotence"
//           ],
//           "keywords": [
//             "Benign Prostatic Hyperplasia (BPH)",
//             "Erectile Dysfunction (ED)"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "NA"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "CROSSOVER",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "DOUBLE"
//             }
//           },
//           "enrollmentInfo": {
//             "count": 40,
//             "type": "ESTIMATED"
//           }
//         },
//         "armsInterventionsModule": {
//           "interventions": [
//             {
//               "type": "DRUG",
//               "name": "Vardenafil 10mg"
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo",
//               "timeFrame": "From half hour prior to till six hour after administration of the drug (baseline)"
//             }
//           ],
//           "secondaryOutcomes": [
//             {
//               "measure": "Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP)",
//               "timeFrame": "From half hour prior to till six hour after administration of the drug (baseline)"
//             },
//             {
//               "measure": "Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after administration of the drug",
//               "timeFrame": "From half hour prior to till six hour after administration of the drug (baseline)"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 50 to 80 years old\n* Clinically diagnosed to have lower urinary tract symptoms secondary to BPH:\n\n  1. Suffered from lower urinary tract symptoms with International Prostate Symptom Score (IPSS) \\>=8\n  2. Detectable prostatic enlargement determined by Digital Rectum Examination (DRE)\n  3. Urinary flow between 5 to 15ml/second in a total void volume \\>=150mL\n* Currently on regular doxazosin GITS once-daily for at least 4 weeks without clinically significant side effects\n* Complaints of erectile dysfunction with Erectile Function domain (EF) of the International Index of Erectile Function (IIEF) score \\<= 21\n\nExclusion Criteria:\n\n* Congestive heart failure, unstable angina, arrhythmia, myocardial infraction\n* Hypertension or on any antihypertensive agents\n* Take nitrate and medication contradicted to vardenafil\n* Uncontrolled or poorly controlled diabetes mellitus\n* Intolerance or contra-indicated for the use of vardenafil\n* Hepatic disorder",
//           "sex": "MALE",
//           "minimumAge": "50 Years",
//           "maximumAge": "80 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "overallOfficials": [
//             {
//               "name": "Chi Fai Ng, Dr",
//               "affiliation": "Department of Surgery, Division of Urology, The Chinese University of Hong Kong",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "Prince of Wales Hospital",
//               "city": "Hong Kong",
//               "country": "China",
//               "geoPoint": {
//                 "lat": 22.39407,
//                 "lon": 114.13737
//               }
//             }
//           ]
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D007172",
//               "term": "Erectile Dysfunction"
//             },
//             {
//               "id": "D011470",
//               "term": "Prostatic Hyperplasia"
//             },
//             {
//               "id": "D006965",
//               "term": "Hyperplasia"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D010335",
//               "term": "Pathologic Processes"
//             },
//             {
//               "id": "D005832",
//               "term": "Genital Diseases, Male"
//             },
//             {
//               "id": "D000091662",
//               "term": "Genital Diseases"
//             },
//             {
//               "id": "D000091642",
//               "term": "Urogenital Diseases"
//             },
//             {
//               "id": "D012735",
//               "term": "Sexual Dysfunction, Physiological"
//             },
//             {
//               "id": "D052801",
//               "term": "Male Urogenital Diseases"
//             },
//             {
//               "id": "D020018",
//               "term": "Sexual Dysfunctions, Psychological"
//             },
//             {
//               "id": "D001523",
//               "term": "Mental Disorders"
//             },
//             {
//               "id": "D011469",
//               "term": "Prostatic Diseases"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M10217",
//               "name": "Erectile Dysfunction",
//               "asFound": "Erectile Dysfunction",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M14334",
//               "name": "Prostatic Hyperplasia",
//               "asFound": "Prostatic Hyperplasia",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M10016",
//               "name": "Hyperplasia",
//               "asFound": "Hyperplasia",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M2876",
//               "name": "Genital Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M8944",
//               "name": "Genital Diseases, Male",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M2875",
//               "name": "Urogenital Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M15546",
//               "name": "Sexual Dysfunction, Physiological",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M27095",
//               "name": "Male Urogenital Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M21873",
//               "name": "Sexual Dysfunctions, Psychological",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M14473",
//               "name": "Psychotic Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M4815",
//               "name": "Mental Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M14333",
//               "name": "Prostatic Diseases",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BXS",
//               "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
//             },
//             {
//               "abbrev": "BXM",
//               "name": "Behaviors and Mental Disorders"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             },
//             {
//               "abbrev": "BC23",
//               "name": "Symptoms and General Pathology"
//             }
//           ]
//         },
//         "interventionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D000069058",
//               "term": "Vardenafil Dihydrochloride"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D014665",
//               "term": "Vasodilator Agents"
//             },
//             {
//               "id": "D058986",
//               "term": "Phosphodiesterase 5 Inhibitors"
//             },
//             {
//               "id": "D010726",
//               "term": "Phosphodiesterase Inhibitors"
//             },
//             {
//               "id": "D004791",
//               "term": "Enzyme Inhibitors"
//             },
//             {
//               "id": "D045504",
//               "term": "Molecular Mechanisms of Pharmacological Action"
//             },
//             {
//               "id": "D064804",
//               "term": "Urological Agents"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M19586",
//               "name": "Doxazosin",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M350",
//               "name": "Vardenafil Dihydrochloride",
//               "asFound": "Premature Infants",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M17412",
//               "name": "Vasodilator Agents",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M29332",
//               "name": "Phosphodiesterase 5 Inhibitors",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M13629",
//               "name": "Phosphodiesterase Inhibitors",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7951",
//               "name": "Enzyme Inhibitors",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "AnAg",
//               "name": "Antihypertensive Agents"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             },
//             {
//               "abbrev": "VaDiAg",
//               "name": "Vasodilator Agents"
//             },
//             {
//               "abbrev": "Urol",
//               "name": "Urological Agents"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT06714279",
//           "orgStudyIdInfo": {
//             "id": "24.71"
//           },
//           "organization": {
//             "fullName": "Royal College of Surgeons, Ireland",
//             "class": "OTHER"
//           },
//           "briefTitle": "Laparoscopic-Assisted Transversus Abdominus Plane Block Versus Intraperitoneal Irrigation of Local Anesthetic for Patients Undergoing Laparoscopic Cholecystectomy",
//           "officialTitle": "Laparoscopic-Assisted Transversus Abdominus Plane Block Versus Intraperitoneal Irrigation of Local Anesthetic for Patients Undergoing Laparoscopic Cholecystectomy - a Prospective, Randomised Clinical Trial"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2024-11",
//           "overallStatus": "NOT_YET_RECRUITING",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2025-01",
//             "type": "ESTIMATED"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2025-01",
//             "type": "ESTIMATED"
//           },
//           "completionDateStruct": {
//             "date": "2025-01",
//             "type": "ESTIMATED"
//           },
//           "studyFirstSubmitDate": "2024-11-23",
//           "studyFirstSubmitQcDate": "2024-11-27",
//           "studyFirstPostDateStruct": {
//             "date": "2024-12-03",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2024-11-27",
//           "lastUpdatePostDateStruct": {
//             "date": "2024-12-03",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "PRINCIPAL_INVESTIGATOR",
//             "investigatorFullName": "Matthew Davey",
//             "investigatorTitle": "Specialist Registrar in General Surgery",
//             "investigatorAffiliation": "Royal College of Surgeons, Ireland"
//           },
//           "leadSponsor": {
//             "name": "Royal College of Surgeons, Ireland",
//             "class": "OTHER"
//           }
//         },
//         "oversightModule": {
//           "oversightHasDmc": true,
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": false,
//           "isUsExport": false
//         },
//         "descriptionModule": {
//           "briefSummary": "This study is being performed to investigate whether the administration of local anaesthetic into the muscles in the abdomen or onto squirting the local anaesthetic onto the liver following keyhole gallbladder surgery is more beneficial in reducing pain post-operatively.\n\nKeyhole gallbladder surgery is typically performed under general anaesthesia (or while the patient is 'fully asleep'), however doctors use other pain relief types to reduce pain after the operation. One of these options is local anaesthetic, which involves the injection of an medication into or onto the part of the body which has been operated on. The reason for doing this is to reduce the pain felt by the patient in the part if the body where the operation occurred. The best way of using these medications remain unclear.\n\nThe local anaesthetic being used in the study is fully approved for use in Ireland and the drug itself is not being tested. In other words, the drug is not an experimental drug. Local anaesthetic drugs are given in different ways in patients who have just had the keyhole surgery on their gall bladder (this is the surgery that you are about to have).\n\nTherefore, the aim of this study is to compare two ways of giving patients these local anaesthetic medications following key-hole gallbladder surgery. These include (1) injecting the medication into the skin at the surgical wounds and squirting it onto the liver (where the gallbladder has been removed from), or (2) injecting the medication into the skin at the surgical wounds and into the muscles in the abdomen (known formally as a transversus abdominus plane block).",
//           "detailedDescription": "Laparoscopic cholecystectomy remains the cornerstone in treating benign diseases of the gallbladder and biliary tree, with approximately 5,000 of these procedures being performed annually in the Republic of Ireland. While significant complications, including bile leak, common bile duct injury (CBDI), and converting to an open incision, are typically discussed in detail when counselling patients in the preoperative setting, post-operative pain in the first 24-hours after surgery remains the main barrier of early discharge following the procedure. To counteract this issue, multimodal analgesic strategies have practically been adopted to minimise post-operative pain following laparoscopic cholecystectomy, as outlined by the Procedure Specific Post-Operative Pain Management (PROSPECT) in their review and recommendations. More specifically, the PROSPECT guidelines provide GRADE A recommendations in support of both standard paracetamol and non-steroidal anti-inflammatory (or cyclooxygenase-2 specific inhibitors), combined with surgical site local anaesthetic infiltration in patients in the peri-operative setting 'as the first line for routine use'.\n\nDespite these recommendations, there remains ambiguity in the surgical literature surrounding to the optimal strategy for the infiltration of local anaesthetic; previous data has coherently demonstrated the superiority of surgical site wound infiltration, intraperitoneal infiltration and intra-abdominal wall blocks with local anaesthetic agents in reducing post-operative pain relative to placebo. In particular, data from a previous randomised clinical trial (RCT) has indicated that infiltrating the gallbladder fossa with local anaesthetic is more effective in reducing post-operative pain than local wound infiltration, however these results were subsequently refuted in a sequential RCT, leaving ambiguity as to the effect of this technique in reducing post-operative pain. Furthermore, recent RCTs have demonstrated that infiltration of local anaesthetic into either transversus abdominus plane (TAP) or the rectus sheath intraoperatively reduced post-operative pain compared to infiltration into the wound alone, directly reducing the post-operative morphine requirement. While ultrasound-guided transversus abdominus plane (US-TAP) are now commonly utilised in the perioperative setting following laparoscopic cholecystectomy, the suitability of a laparoscopic-guided approach (L-TAP) has been less well established within the surgical literature.\n\nGiven the contrasting results of these previous studies, there remains no consensus as to the validity of using L-TAP or intraperitoneal infiltration of local anaesthetic to the liver bed as contemporary modes of delivering local anaesthetic following laparoscopic cholecystectomy. Accordingly, the aim of this study was to perform a prospective, randomised study evaluating the benefit of L-TAP or intraperitoneal infiltration in patients indicated to undergo laparoscopic cholecystectomy. This study is a parallel two-arm study which will evaluate outcomes following local anesthetic infiltration (1) directly into the laparoscopic port sites combined with intraperitoneal infiltration, and (2) directly into the laparoscopic port sites combined with laparoscopic infiltration via TAP block."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Laparoscopic Cholecystectomy",
//             "TAP Block",
//             "Local Anesthetic"
//           ],
//           "keywords": [
//             "Laparoscopic cholecystectomy",
//             "TAP block",
//             "Transversus abdominus plane block",
//             "Local anesthetic"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "PHASE1"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "PARALLEL",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "NONE"
//             }
//           },
//           "enrollmentInfo": {
//             "count": 144,
//             "type": "ESTIMATED"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "Study Group - Tap Block",
//               "type": "OTHER",
//               "description": "Study Group: Study group: Laparoscopic Transversus Abdominis Plane in four points: above the umbilicus on the left side; dose calculation 2.5mg per body weight.\n\nAfter the cholecystectomy is done and just before withdrawing port and deflating the abdomen, the operating surgeon will advance a needle into the abdominal wall to the level of the preperitoneal space. Once the needle tip is seen, it is withdrawn slowly and gently about 0.5cm above/superficial to the transversus abdominis (TA) muscle. The surgeon then infiltrates the local anaesthetic into the plane, and the right plane is confirmed by visualising a uniform protrusion downwards of the TA muscle fibres (Doyle's bulge). Seeing a preperitoneal or muscle blister laparoscopically indicates that the infiltration is deeper to this plane, and the needle should be withdrawn more superficially.",
//               "interventionNames": [
//                 "Drug: Tap Block - Bupivacaine"
//               ]
//             },
//             {
//               "label": "Control Group - Intraperitoneal Local Anesthetic onto Liver",
//               "type": "PLACEBO_COMPARATOR",
//               "description": "Administration of local anesthetic to the liver using, dose calculation 2.5mg per body weight.",
//               "interventionNames": [
//                 "Drug: Intraperitoneal infiltration to liver"
//               ]
//             }
//           ],
//           "interventions": [
//             {
//               "type": "DRUG",
//               "name": "Tap Block - Bupivacaine",
//               "description": "The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)",
//               "armGroupLabels": [
//                 "Study Group - Tap Block"
//               ]
//             },
//             {
//               "type": "DRUG",
//               "name": "Intraperitoneal infiltration to liver",
//               "description": "The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)",
//               "armGroupLabels": [
//                 "Control Group - Intraperitoneal Local Anesthetic onto Liver"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Post operative pain measured via Visual Anaolgue Scores",
//               "description": "The primary objective for the study is to quantify and analyse differences in the post-operative resting and shoulder tip pain as measured using VAS at 1-hour, 3-hours, 6-hours, 12-hours and 24-hours following laparoscopic cholecystectomy. Thereafter, the further opioid analgesic requirements for each patient will be recorded for the duration of their inpatient stay and also the total sum of opioids prescribed for these patients on discharge (measured using morphine equivalents).",
//               "timeFrame": "1-hour, 3-hours, 6-hours, 12-hours and 24-hours"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients aged 18 years or older will be considered for recruitment into this study if they are indicated to undergo elective laparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* Patients failing to meet the above inclusion criteria.",
//           "healthyVolunteers": false,
//           "sex": "ALL",
//           "minimumAge": "18 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "centralContacts": [
//             {
//               "name": "Matthew G Davey, MB BCh BAO MuCh MRCSI PhD",
//               "role": "CONTACT",
//               "phone": "+353180320000",
//               "email": "matthewdavey21@rcsi.ie"
//             }
//           ],
//           "overallOfficials": [
//             {
//               "name": "Arnold DK Hill, MB MCh FRCS",
//               "affiliation": "RCSI",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "UNDECIDED"
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "interventionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D002045",
//               "term": "Bupivacaine"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D000779",
//               "term": "Anesthetics, Local"
//             },
//             {
//               "id": "D000777",
//               "term": "Anesthetics"
//             },
//             {
//               "id": "D002492",
//               "term": "Central Nervous System Depressants"
//             },
//             {
//               "id": "D045505",
//               "term": "Physiological Effects of Drugs"
//             },
//             {
//               "id": "D018689",
//               "term": "Sensory System Agents"
//             },
//             {
//               "id": "D018373",
//               "term": "Peripheral Nervous System Agents"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M5315",
//               "name": "Bupivacaine",
//               "asFound": "Following",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M4107",
//               "name": "Anesthetics",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M4109",
//               "name": "Anesthetics, Local",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M11110",
//               "name": "Liver Extracts",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "CNSDep",
//               "name": "Central Nervous System Depressants"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             },
//             {
//               "abbrev": "Hemat",
//               "name": "Hematinics"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT05600179",
//           "orgStudyIdInfo": {
//             "id": "0110/2022"
//           },
//           "organization": {
//             "fullName": "Federico II University",
//             "class": "OTHER"
//           },
//           "briefTitle": "OCTA in Epivascular Glia After Dex Implant",
//           "officialTitle": "Evaluation of Changes in Epivascular Glia Before and After Intravitreal Dexamethasone Implant : an OCT Pilot Study"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2022-12",
//           "overallStatus": "COMPLETED",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2021-01-01",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2022-09-30",
//             "type": "ACTUAL"
//           },
//           "completionDateStruct": {
//             "date": "2022-09-30",
//             "type": "ACTUAL"
//           },
//           "studyFirstSubmitDate": "2022-10-26",
//           "studyFirstSubmitQcDate": "2022-10-28",
//           "studyFirstPostDateStruct": {
//             "date": "2022-10-31",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2022-12-06",
//           "lastUpdatePostDateStruct": {
//             "date": "2022-12-08",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "PRINCIPAL_INVESTIGATOR",
//             "investigatorFullName": "Gilda Cennamo",
//             "investigatorTitle": "professor",
//             "investigatorAffiliation": "Federico II University"
//           },
//           "leadSponsor": {
//             "name": "Federico II University",
//             "class": "OTHER"
//           }
//         },
//         "oversightModule": {
//           "oversightHasDmc": false,
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": false
//         },
//         "descriptionModule": {
//           "briefSummary": "The aim of this prospective study was for the first time, to analyze specific morphologic features in diabetic eyes with macular oedema, such as changes of the foveal avascular zone and the presence of epivascular glia, and see how they would change after dexamethasone intravitreal implant"
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Diabetic Retinopathy"
//           ]
//         },
//         "designModule": {
//           "studyType": "OBSERVATIONAL",
//           "patientRegistry": false,
//           "designInfo": {
//             "observationalModel": "COHORT",
//             "timePerspective": "PROSPECTIVE"
//           },
//           "enrollmentInfo": {
//             "count": 38,
//             "type": "ACTUAL"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "patients with diabetic macular edema",
//               "interventionNames": [
//                 "Drug: Dexamethasone intravitreal implant"
//               ]
//             },
//             {
//               "label": "healthy patients"
//             }
//           ],
//           "interventions": [
//             {
//               "type": "DRUG",
//               "name": "Dexamethasone intravitreal implant",
//               "description": "Dexamethasone intravitreal implant",
//               "armGroupLabels": [
//                 "patients with diabetic macular edema"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema",
//               "timeFrame": "up to 6 months"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n* diabetic retinopathy complicated by macular edema\n\nExclusion Criteria:\n\n* congenital eye disorders,\n* previous diagnosis of other ocular diseases\n* history of vitreous hemorrhage",
//           "healthyVolunteers": true,
//           "sex": "ALL",
//           "minimumAge": "18 Years",
//           "maximumAge": "80 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ],
//           "studyPopulation": "The participans were older than 18 years with diagnosis of inflammatory diabetic macular edema glaucoma..",
//           "samplingMethod": "NON_PROBABILITY_SAMPLE"
//         },
//         "contactsLocationsModule": {
//           "locations": [
//             {
//               "facility": "University of Naples \"Federico II\"",
//               "city": "Naples",
//               "zip": "80100",
//               "country": "Italy",
//               "geoPoint": {
//                 "lat": 40.85216,
//                 "lon": 14.26811
//               }
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "YES"
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D003930",
//               "term": "Diabetic Retinopathy"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D012164",
//               "term": "Retinal Diseases"
//             },
//             {
//               "id": "D005128",
//               "term": "Eye Diseases"
//             },
//             {
//               "id": "D003925",
//               "term": "Diabetic Angiopathies"
//             },
//             {
//               "id": "D014652",
//               "term": "Vascular Diseases"
//             },
//             {
//               "id": "D002318",
//               "term": "Cardiovascular Diseases"
//             },
//             {
//               "id": "D048909",
//               "term": "Diabetes Complications"
//             },
//             {
//               "id": "D003920",
//               "term": "Diabetes Mellitus"
//             },
//             {
//               "id": "D004700",
//               "term": "Endocrine System Diseases"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M14999",
//               "name": "Retinal Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7125",
//               "name": "Diabetic Retinopathy",
//               "asFound": "Diabetic Retinopathy",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M8271",
//               "name": "Eye Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7120",
//               "name": "Diabetic Angiopathies",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M17400",
//               "name": "Vascular Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7115",
//               "name": "Diabetes Mellitus",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M26004",
//               "name": "Diabetes Complications",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7862",
//               "name": "Endocrine System Diseases",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC11",
//               "name": "Eye Diseases"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             },
//             {
//               "abbrev": "BC14",
//               "name": "Heart and Blood Diseases"
//             },
//             {
//               "abbrev": "BC19",
//               "name": "Gland and Hormone Related Diseases"
//             },
//             {
//               "abbrev": "BC18",
//               "name": "Nutritional and Metabolic Diseases"
//             }
//           ]
//         },
//         "interventionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D003907",
//               "term": "Dexamethasone"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D000893",
//               "term": "Anti-Inflammatory Agents"
//             },
//             {
//               "id": "D000932",
//               "term": "Antiemetics"
//             },
//             {
//               "id": "D001337",
//               "term": "Autonomic Agents"
//             },
//             {
//               "id": "D018373",
//               "term": "Peripheral Nervous System Agents"
//             },
//             {
//               "id": "D045505",
//               "term": "Physiological Effects of Drugs"
//             },
//             {
//               "id": "D005765",
//               "term": "Gastrointestinal Agents"
//             },
//             {
//               "id": "D005938",
//               "term": "Glucocorticoids"
//             },
//             {
//               "id": "D006728",
//               "term": "Hormones"
//             },
//             {
//               "id": "D006730",
//               "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
//             },
//             {
//               "id": "D018931",
//               "term": "Antineoplastic Agents, Hormonal"
//             },
//             {
//               "id": "D000970",
//               "term": "Antineoplastic Agents"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M7102",
//               "name": "Dexamethasone",
//               "asFound": "First",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M235549",
//               "name": "Dexamethasone acetate",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M4217",
//               "name": "Anti-Inflammatory Agents",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M4251",
//               "name": "Antiemetics",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M8881",
//               "name": "Gastrointestinal Agents",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M9047",
//               "name": "Glucocorticoids",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M9789",
//               "name": "Hormones",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M9788",
//               "name": "Hormone Antagonists",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M20966",
//               "name": "Antineoplastic Agents, Hormonal",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "Infl",
//               "name": "Anti-Inflammatory Agents"
//             },
//             {
//               "abbrev": "ANeo",
//               "name": "Antineoplastic Agents"
//             },
//             {
//               "abbrev": "AnEm",
//               "name": "Antiemetics"
//             },
//             {
//               "abbrev": "Gast",
//               "name": "Gastrointestinal Agents"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT01511679",
//           "orgStudyIdInfo": {
//             "id": "BANC RFA-AA-12-006"
//           },
//           "organization": {
//             "fullName": "Boston Children's Hospital",
//             "class": "OTHER"
//           },
//           "briefTitle": "Brain-imaging and Adolescent Neuroscience Consortium",
//           "officialTitle": "Brain-imaging and Adolescent Neuroscience Consortium",
//           "acronym": "BANC"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2013-01",
//           "overallStatus": "WITHDRAWN",
//           "whyStopped": "The project was not funded.",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2012-09"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2017-03",
//             "type": "ESTIMATED"
//           },
//           "completionDateStruct": {
//             "date": "2017-09",
//             "type": "ESTIMATED"
//           },
//           "studyFirstSubmitDate": "2012-01-13",
//           "studyFirstSubmitQcDate": "2012-01-18",
//           "studyFirstPostDateStruct": {
//             "date": "2012-01-19",
//             "type": "ESTIMATED"
//           },
//           "lastUpdateSubmitDate": "2013-01-02",
//           "lastUpdatePostDateStruct": {
//             "date": "2013-01-03",
//             "type": "ESTIMATED"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "SPONSOR"
//           },
//           "leadSponsor": {
//             "name": "Boston Children's Hospital",
//             "class": "OTHER"
//           },
//           "collaborators": [
//             {
//               "name": "Massachusetts General Hospital",
//               "class": "OTHER"
//             },
//             {
//               "name": "Mclean Hospital",
//               "class": "OTHER"
//             },
//             {
//               "name": "Massachusetts Institute of Technology",
//               "class": "OTHER"
//             }
//           ]
//         },
//         "oversightModule": {
//           "oversightHasDmc": false
//         },
//         "descriptionModule": {
//           "briefSummary": "This is a multi-site study of adolescents 12-21 years-of-age to evaluate the long and shorter-term effect of adolescent alcohol use on the developing brain.",
//           "detailedDescription": "The overall specific aims of this study are to: 1) assess the short and long-term consequences of alcohol exposure on brain, cognitive, and emotional/regulatory development during preadolescence and adolescence; 2) determine the effects of timing, dose, and duration of alcohol on brain and cognitive development; 3) assess recovery of neural and behavioral function to determine if the plasticity of the adolescent brain makes it more or less vulnerable to alcohol's acute and chronic effects; 4) understand how other key covariates (e.g., existing or emerging psychopathology, family history of alcoholism, demographics, pubertal development) factor into alcohol's effects on the brain; and 5) identify early neural, cognitive, and affective markers that may predict alcohol abuse and dependence during adolescence and/or adulthood."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Alcohol Abuse"
//           ],
//           "keywords": [
//             "Alcohol abuse"
//           ]
//         },
//         "designModule": {
//           "studyType": "OBSERVATIONAL",
//           "designInfo": {
//             "observationalModel": "COHORT",
//             "timePerspective": "PROSPECTIVE"
//           },
//           "bioSpec": {
//             "retention": "SAMPLES_WITH_DNA",
//             "description": "Saliva DNA samples for future analyses."
//           },
//           "enrollmentInfo": {
//             "count": 0,
//             "type": "ACTUAL"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "Alcohol-naive adolescents",
//               "description": "A general population longitudinal cohort of alcohol-nave (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o)."
//             },
//             {
//               "label": "Treatment sample",
//               "description": "A sample of adolescents who have a \\>1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan"
//             },
//             {
//               "label": "High risk sample",
//               "description": "High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n* able to read and understand English\n* available for follow-up\n* parental consent/adolescent assent for those 12-17 years\n* consent for those 18-21 years\n\nExclusion Criteria:\n\n* Weight \\> 300 lbs\n* braces or unremovable embedded metal\n* claustrophobia or inability to lie still in MRI machine\n* current or past 12-mos pregnancy (females)\n* requires urgent medical/mental health care",
//           "healthyVolunteers": false,
//           "sex": "ALL",
//           "minimumAge": "12 Years",
//           "maximumAge": "21 Years",
//           "stdAges": [
//             "CHILD",
//             "ADULT"
//           ],
//           "studyPopulation": "Male and female adolescents 12-21 years-of-age presenting for care at one of the participating medical clinics",
//           "samplingMethod": "NON_PROBABILITY_SAMPLE"
//         },
//         "contactsLocationsModule": {
//           "overallOfficials": [
//             {
//               "name": "John R Knight, MD",
//               "affiliation": "Boston Children's Hospital",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "Gordon J Harris, PhD",
//               "affiliation": "Massachusetts General Hospital",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "Simon Warfield, PhD",
//               "affiliation": "Boston Children's Hospital",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "Avram Holmes, PhD",
//               "affiliation": "Harvard University",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "Scott Lukas, PhD",
//               "affiliation": "Mclean Hospital",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "Marisa Silveri, PhD",
//               "affiliation": "Mclean Hospital",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "Marlene Oscar Berman, PhD",
//               "affiliation": "Boston University",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             },
//             {
//               "name": "John Gabrieli, PhD",
//               "affiliation": "Massachusetts Institute of Technology",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "McLean Hospital",
//               "city": "Belmont",
//               "state": "Massachusetts",
//               "zip": "02478",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.39593,
//                 "lon": -71.17867
//               }
//             },
//             {
//               "facility": "Massachusetts General Hospital",
//               "city": "Boston",
//               "state": "Massachusetts",
//               "zip": "02114",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.35843,
//                 "lon": -71.05977
//               }
//             },
//             {
//               "facility": "Boston University School of Medicine",
//               "city": "Boston",
//               "state": "Massachusetts",
//               "zip": "02118",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.35843,
//                 "lon": -71.05977
//               }
//             },
//             {
//               "facility": "Massachusetts Institute of Technology",
//               "city": "Cambridge",
//               "state": "Massachusetts",
//               "zip": "02139",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.3751,
//                 "lon": -71.10561
//               }
//             }
//           ]
//         },
//         "referencesModule": {
//           "seeAlsoLinks": [
//             {
//               "label": "Center for Adolescent Substance Abuse Research at Children's Hospital Boston",
//               "url": "http://www.ceasar.org"
//             }
//           ]
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D000437",
//               "term": "Alcoholism"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D019973",
//               "term": "Alcohol-Related Disorders"
//             },
//             {
//               "id": "D019966",
//               "term": "Substance-Related Disorders"
//             },
//             {
//               "id": "D064419",
//               "term": "Chemically-Induced Disorders"
//             },
//             {
//               "id": "D001523",
//               "term": "Mental Disorders"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M3783",
//               "name": "Alcoholism",
//               "asFound": "Alcohol Abuse",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M21842",
//               "name": "Alcohol-Related Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M21837",
//               "name": "Substance-Related Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M30302",
//               "name": "Chemically-Induced Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M14473",
//               "name": "Psychotic Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M4815",
//               "name": "Mental Disorders",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC25",
//               "name": "Substance Related Disorders"
//             },
//             {
//               "abbrev": "BXM",
//               "name": "Behaviors and Mental Disorders"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             }
//           ]
//         },
//         "interventionBrowseModule": {
//           "browseLeaves": [
//             {
//               "id": "M3777",
//               "name": "Ethanol",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "Infe",
//               "name": "Anti-Infective Agents"
//             },
//             {
//               "abbrev": "CNSDep",
//               "name": "Central Nervous System Depressants"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT05602779",
//           "orgStudyIdInfo": {
//             "id": "22-08-7372"
//           },
//           "organization": {
//             "fullName": "University of Notre Dame",
//             "class": "OTHER"
//           },
//           "briefTitle": "Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents",
//           "officialTitle": "Leveraging Noninvasive Transcutaneous Vagus Nerve Stimulation and Smartphone Technology to Reduce Suicidal Behaviors and Suicide Among Highly Vulnerable Adolescents"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2023-11",
//           "overallStatus": "RECRUITING",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2023-10-08",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2027-04-15",
//             "type": "ESTIMATED"
//           },
//           "completionDateStruct": {
//             "date": "2027-09-30",
//             "type": "ESTIMATED"
//           },
//           "studyFirstSubmitDate": "2022-10-06",
//           "studyFirstSubmitQcDate": "2022-11-01",
//           "studyFirstPostDateStruct": {
//             "date": "2022-11-02",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2023-11-29",
//           "lastUpdatePostDateStruct": {
//             "date": "2023-12-06",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "PRINCIPAL_INVESTIGATOR",
//             "investigatorFullName": "Theodore Beauchaine",
//             "investigatorTitle": "William K Warren Professor of Psychology",
//             "investigatorAffiliation": "University of Notre Dame"
//           },
//           "leadSponsor": {
//             "name": "University of Notre Dame",
//             "class": "OTHER"
//           },
//           "collaborators": [
//             {
//               "name": "University of Rochester",
//               "class": "OTHER"
//             }
//           ]
//         },
//         "oversightModule": {
//           "oversightHasDmc": true,
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": true,
//           "isUsExport": false
//         },
//         "descriptionModule": {
//           "briefSummary": "Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence.\n\nCurrent face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.",
//           "detailedDescription": "Over the past two decades, suicide rates have increased nearly 35% in the U.S., with upward trends in nearly all demographic groups. Further increases have occurred since the COVID-19 pandemic began. Despite ambitious goals for reducing suicides and significant federal and private investment, suicide rates continue to rise unabated. To date, the predominant approach to mitigating suicide risk in the U.S. is secondary prevention. Typically, these programs identify risk of recurrence among those who have already attempted suicide at least once. Although secondary prevention is crucial, the majority of deaths by suicide occur on first attempt. Thus, targeted primary prevention earlier in development is essential. Most current primary prevention programs are intensive, expensive, and delivered by highly trained mental health providers, who are in short supply. Traditional face-to-face therapy is also unavailable to many who live in underserved communities, and disliked by adolescents, who much prefer digital delivery on their devices. This high-risk, high-reward proposal addresses these limitations and needs. We use an experimental therapeutics approach to evaluate the independent and combined efficacies of two unconventional but scalable interventions: transcutaneous vagus nerve stimulation (tVNS) to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. These low-cost interventions, which hold strong promise but have not been used before, can reach large numbers of adolescents, with much potential to reduce prospective suicide risk. We will enroll 212 adolescents, ages 13-17 years, who show elevations on at least two prominent risk factors for suicide (e.g., self-injury, maltreatment).\n\nUsing a 2  2 design, adolescents will be assigned randomly to receive 30 days of treatment with:\n\n1. tVNS to target emotion dysregulation,\n2. a peer-support phone app to target social isolation,\n3. tVNS + a peer-support phone app, or\n4. enhanced treatment as usual with monitoring and access to resources.\n\nIntervention effects on mechanisms (emotion dysregulation, social isolation) proximal efficacy signals (e.g., physiological reactivity, self-harm) and target outcomes (suicidal ideation, suicidal behaviors) will be evaluated immediately post-intervention and at one-year follow-up. Treatment data will be monitored daily to fine-tune dosing of both interventions. This transformative and innovative proposal tests two novel, scalable preventive interventions designed to \"meet adolescents where they are\" by using digital technologies to address core mechanisms of suicide risk."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Self Harm",
//             "Suicidal Ideation"
//           ],
//           "keywords": [
//             "Self Harm",
//             "Suicide Prevention"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "NA"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "PARALLEL",
//             "interventionModelDescription": "There will be four distinct treatment groups, each participant will be randomly assigned to one of the four groups.",
//             "primaryPurpose": "PREVENTION",
//             "maskingInfo": {
//               "masking": "SINGLE",
//               "whoMasked": [
//                 "PARTICIPANT"
//               ]
//             }
//           },
//           "enrollmentInfo": {
//             "count": 212,
//             "type": "ESTIMATED"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "tVNS Program",
//               "type": "EXPERIMENTAL",
//               "description": "Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.",
//               "interventionNames": [
//                 "Device: tVns Program"
//               ]
//             },
//             {
//               "label": "Phone App Program",
//               "type": "EXPERIMENTAL",
//               "description": "Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.",
//               "interventionNames": [
//                 "Other: Phone App Program"
//               ]
//             },
//             {
//               "label": "tVNS and Phone App Program",
//               "type": "EXPERIMENTAL",
//               "description": "Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.",
//               "interventionNames": [
//                 "Combination Product: tVNS and Phone App Program"
//               ]
//             },
//             {
//               "label": "Enhanced Treatment as Usual",
//               "type": "SHAM_COMPARATOR",
//               "description": "Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.",
//               "interventionNames": [
//                 "Other: Enhanced Treatment as Usual"
//               ]
//             }
//           ],
//           "interventions": [
//             {
//               "type": "DEVICE",
//               "name": "tVns Program",
//               "description": "Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.",
//               "armGroupLabels": [
//                 "tVNS Program"
//               ]
//             },
//             {
//               "type": "OTHER",
//               "name": "Phone App Program",
//               "description": "Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.",
//               "armGroupLabels": [
//                 "Phone App Program"
//               ]
//             },
//             {
//               "type": "COMBINATION_PRODUCT",
//               "name": "tVNS and Phone App Program",
//               "description": "Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.",
//               "armGroupLabels": [
//                 "tVNS and Phone App Program"
//               ]
//             },
//             {
//               "type": "OTHER",
//               "name": "Enhanced Treatment as Usual",
//               "description": "Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.",
//               "armGroupLabels": [
//                 "Enhanced Treatment as Usual"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days",
//               "description": "Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge.\n\nAll participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms.",
//               "timeFrame": "30 Days"
//             },
//             {
//               "measure": "Improved Reports of Social Isolation and Loneliness",
//               "description": "Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen.\n\nSome teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teen's self-reported feelings of isolation and loneliness.\n\nFor the rate of change, we will use percentile ranking vis-a-vis national norms.",
//               "timeFrame": "30 Days"
//             },
//             {
//               "measure": "Improved Results from Participant's Typical Treatment",
//               "description": "Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm.\n\nFor the rate of change, we will use percentile ranking vis-a-vis national norms.",
//               "timeFrame": "30 Days"
//             }
//           ],
//           "secondaryOutcomes": [
//             {
//               "measure": "Adherence to tVNS and Phone App intervention from Baseline to 30 days.",
//               "description": "Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app.",
//               "timeFrame": "30 Days"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged between 13 and 17 years,\n* Attend in person meetings in South Bend, IN or Rochester, NY. and,\n\nTwo of the following which will be scored during the phone screen:\n\n* Engaged in non-suicidal self-harm 3 times in the past 6 months or more than 5 times in their life time, with one occurrence in the past year.\n* Show high scores on emotional dysregulation\n* Show high scores on social isolation\n* Show high scores on impulsivity\n* Show high scores on depression\n* Engage in alcohol or other substance use\n\nExclusion Criteria:\n\n* Parent reported autism or schizophrenia\n* Implanted pacemaker or cardiac defibrillator, other implanted or metallic device\n* Pregnant or breast feeding\n* History of seizures or epilepsy\n* TMJ Disorder\n* Bells' Palsy\n* Impaired cranial nerve function\n* Facial Pain",
//           "healthyVolunteers": false,
//           "sex": "ALL",
//           "minimumAge": "13 Years",
//           "maximumAge": "17 Years",
//           "stdAges": [
//             "CHILD"
//           ]
//         },
//         "contactsLocationsModule": {
//           "centralContacts": [
//             {
//               "name": "Cheryl Lee, MS",
//               "role": "CONTACT",
//               "phone": "574-631-5097",
//               "email": "clee21@nd.edu"
//             }
//           ],
//           "overallOfficials": [
//             {
//               "name": "Theodore Beauchaine, PhD",
//               "affiliation": "William K Warren Foundation Professor of Psychology",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "University of Notre Dame",
//               "status": "RECRUITING",
//               "city": "South Bend",
//               "state": "Indiana",
//               "zip": "46617",
//               "country": "United States",
//               "contacts": [
//                 {
//                   "name": "Jayme Culwell, MSW",
//                   "role": "CONTACT",
//                   "phone": "574-631-1101",
//                   "email": "jculwell@nd.edu"
//                 },
//                 {
//                   "name": "Cheryl Lee, MS",
//                   "role": "CONTACT",
//                   "phone": "(574) 631-0950",
//                   "email": "clee21@nd.edu"
//                 },
//                 {
//                   "name": "Theodore P Beauchaine, PhD",
//                   "role": "PRINCIPAL_INVESTIGATOR"
//                 },
//                 {
//                   "name": "Brooke A Ammerman, PhD",
//                   "role": "PRINCIPAL_INVESTIGATOR"
//                 },
//                 {
//                   "name": "Kristin Valentino, PhD",
//                   "role": "PRINCIPAL_INVESTIGATOR"
//                 }
//               ],
//               "geoPoint": {
//                 "lat": 41.68338,
//                 "lon": -86.25001
//               }
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "NO",
//           "description": "There is no plan to share individual participant data outside of the study team."
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D059020",
//               "term": "Suicidal Ideation"
//             },
//             {
//               "id": "D016728",
//               "term": "Self-Injurious Behavior"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D013405",
//               "term": "Suicide"
//             },
//             {
//               "id": "D001526",
//               "term": "Behavioral Symptoms"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M19089",
//               "name": "Self-Injurious Behavior",
//               "asFound": "Self-harm",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M16191",
//               "name": "Suicide",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M2958",
//               "name": "Suicide Prevention",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M29364",
//               "name": "Suicidal Ideation",
//               "asFound": "Suicidal Ideation",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M4818",
//               "name": "Behavioral Symptoms",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BXM",
//               "name": "Behaviors and Mental Disorders"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT04175379",
//           "orgStudyIdInfo": {
//             "id": "4-2019-0904"
//           },
//           "organization": {
//             "fullName": "Yonsei University",
//             "class": "OTHER"
//           },
//           "briefTitle": "The Effect of Permissive Hypercapnia on Oxygenation and Post-operative Pulmonary Complication During One-lung Ventilation",
//           "officialTitle": "The Effect of Permissive Hypercapnia on Oxygenation and Post-operative Pulmonary Complication During One-lung Ventilation : Prospective, Randomized Controlled Study"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2019-12",
//           "overallStatus": "UNKNOWN",
//           "lastKnownStatus": "ENROLLING_BY_INVITATION",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2019-11-25",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2021-08",
//             "type": "ESTIMATED"
//           },
//           "completionDateStruct": {
//             "date": "2021-10",
//             "type": "ESTIMATED"
//           },
//           "studyFirstSubmitDate": "2019-11-15",
//           "studyFirstSubmitQcDate": "2019-11-21",
//           "studyFirstPostDateStruct": {
//             "date": "2019-11-25",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2019-12-30",
//           "lastUpdatePostDateStruct": {
//             "date": "2020-01-02",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "SPONSOR"
//           },
//           "leadSponsor": {
//             "name": "Yonsei University",
//             "class": "OTHER"
//           }
//         },
//         "oversightModule": {
//           "oversightHasDmc": false,
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": false
//         },
//         "descriptionModule": {
//           "briefSummary": "Permissive hypercapnia increased the survival rate in patients with acute respiratory distress syndrome (ARDS) who required mechanical ventilation in critical care medicine. This has been explained by its association with ventilator induced lung injury. Since then, a protective lung ventilation strategy has been very important, with a low tidal volume of 4-6 ml/kg. Patients undergoing surgery will inevitably require mechanical ventilation. In particular, patients undergoing one lung ventilation for thoracic surgery may have increased airway pressure and a greater chance of ventilator induced lung injury. Recently, protective lung ventilation has been applied to patients undergoing one ung ventilation during thoracic surgery. The purpose of this study is to evaluate the difference in the degree of pulmonary oxygenation and the incidence of postoperative pulmonary complications in hypercapnia induced by controlling the respiratory rate with a constant tidal volume."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Thoracic Surgery"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "NA"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "PARALLEL",
//             "interventionModelDescription": "Random sampling using random numbers is divided into three groups, and the ratio of each group is 1: 1: 1.",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "TRIPLE",
//               "maskingDescription": "Patients, care givers and outcomes assessors are blinded. The investigator should not be included in the blind because they need to adjust the ventilator settings.",
//               "whoMasked": [
//                 "PARTICIPANT",
//                 "CARE_PROVIDER",
//                 "OUTCOMES_ASSESSOR"
//               ]
//             }
//           },
//           "enrollmentInfo": {
//             "count": 279,
//             "type": "ESTIMATED"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "group 40",
//               "type": "EXPERIMENTAL",
//               "description": "In group 40, target PaCO2 is 40 during surgery",
//               "interventionNames": [
//                 "Other: group 40"
//               ]
//             },
//             {
//               "label": "group 50",
//               "type": "EXPERIMENTAL",
//               "description": "In group 50, target PaCO2 is 50 during surgery",
//               "interventionNames": [
//                 "Other: group 50"
//               ]
//             },
//             {
//               "label": "group 60",
//               "type": "EXPERIMENTAL",
//               "description": "In group 60, target PaCO2 is 60 during surgery",
//               "interventionNames": [
//                 "Other: group 60"
//               ]
//             }
//           ],
//           "interventions": [
//             {
//               "type": "OTHER",
//               "name": "group 40",
//               "description": "During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40  5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).",
//               "armGroupLabels": [
//                 "group 40"
//               ]
//             },
//             {
//               "type": "OTHER",
//               "name": "group 50",
//               "description": "During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50  5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).",
//               "armGroupLabels": [
//                 "group 50"
//               ]
//             },
//             {
//               "type": "OTHER",
//               "name": "group 60",
//               "description": "During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60  5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).",
//               "armGroupLabels": [
//                 "group 60"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "PaO2/FiO2 ratio",
//               "description": "(arterial oxygen partial pressure / fractional inspired oxygen) at the time of T2 (PaO2 of ABGA/FiO2) T2",
//               "timeFrame": "about 60 minutes after reaching to the target PaCO2 (T2)"
//             }
//           ],
//           "secondaryOutcomes": [
//             {
//               "measure": "Post-op complication: desaturation event",
//               "description": "desaturation event (\\<90%) the first 3 days after surgery",
//               "timeFrame": "first 3 days after surgery"
//             },
//             {
//               "measure": "Post-op complication: oxygen therapy",
//               "description": "necessity of oxygen therapy within the first 2\\~7 days after surgery hospitalized days, ICU days, expire",
//               "timeFrame": "first 2~7 days after surgery"
//             },
//             {
//               "measure": "Post-op complication",
//               "description": "The presence or absence of post operative complication like pneumonia, acute lung injury, re-intubation, ICU admission, ventilator care, empyema, broncho-pleura fistula, air-leakage, pleural effusion, pulmonary embolism, tracheostomy, wound infection, AKI, MI, etc.",
//               "timeFrame": "30 days after surgery"
//             },
//             {
//               "measure": "Post-op complication: hospitalized days",
//               "description": "length of hospitalized stays CU days, expire",
//               "timeFrame": "30 days after surgery"
//             },
//             {
//               "measure": "Post-op complication: ICU days",
//               "description": "length of ICU stays",
//               "timeFrame": "30 days after surgery"
//             },
//             {
//               "measure": "Dead",
//               "description": "patient has been dead or not",
//               "timeFrame": "30 days after surgery"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult patients aged 40-80 years who are planning to have thoracoscopic single lobectomy or segmentectomy with one lung ventilation during surgery.\n2. American Society of Anesthesiologists (ASA) classification 1\\~3\n\nExclusion Criteria:\n\n1. patients with heart failure (NYHA class III\\~IV)\n2. patients who are having moderate obstructive lung disease or restrictive lung disease\n3. Low DLCO (\\< 75%)\n4. patients with brain disease history or increased ICP\n5. patients with pulmonary hypertension (mean PAP\\>25mmHg)\n6. patients with liver disease (AST level 100 IU/mL or ALT  level 50 IU/L) or kidney disease (Creatine level  1.5 mg/dL)\n7. patients with pre-existing hypercapnia or metabolic acidosis\n8. body mass index (BMI) \\> 30 kg/m2\n9. patients who have had contralateral lung surgery\n10. patients who cannot read explanation and consent form\n11. patients who are pregnant",
//           "healthyVolunteers": true,
//           "sex": "ALL",
//           "minimumAge": "40 Years",
//           "maximumAge": "80 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "locations": [
//             {
//               "facility": "Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine",
//               "city": "Seoul",
//               "zip": "03722",
//               "country": "Korea, Republic of",
//               "geoPoint": {
//                 "lat": 37.566,
//                 "lon": 126.9784
//               }
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "NO"
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D006935",
//               "term": "Hypercapnia"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D012818",
//               "term": "Signs and Symptoms, Respiratory"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M9986",
//               "name": "Hypercapnia",
//               "asFound": "Hypercapnia",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M15623",
//               "name": "Signs and Symptoms, Respiratory",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC23",
//               "name": "Symptoms and General Pathology"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             }
//           ]
//         },
//         "interventionBrowseModule": {
//           "browseLeaves": [
//             {
//               "id": "M4854",
//               "name": "Benzocaine",
//               "relevance": "LOW"
//             },
//             {
//               "id": "T433",
//               "name": "Tannic Acid",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "CNSDep",
//               "name": "Central Nervous System Depressants"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             },
//             {
//               "abbrev": "Ot",
//               "name": "Other Dietary Supplements"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT01126879",
//           "orgStudyIdInfo": {
//             "id": "NCI 09U2"
//           },
//           "secondaryIdInfos": [
//             {
//               "id": "NCI-2010-00941"
//             },
//             {
//               "id": "STU00019487",
//               "type": "OTHER",
//               "domain": "Northwestern University IRB"
//             },
//             {
//               "id": "P50CA090386",
//               "type": "NIH",
//               "link": "https://reporter.nih.gov/quickSearch/P50CA090386"
//             }
//           ],
//           "organization": {
//             "fullName": "Northwestern University",
//             "class": "OTHER"
//           },
//           "briefTitle": "Genistein in Treating Patients With Prostate Cancer",
//           "officialTitle": "Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2019-04",
//           "overallStatus": "TERMINATED",
//           "whyStopped": "Closed due to low accrual",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2011-02-03",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2013-05-09",
//             "type": "ACTUAL"
//           },
//           "completionDateStruct": {
//             "date": "2013-12-28",
//             "type": "ACTUAL"
//           },
//           "studyFirstSubmitDate": "2010-05-18",
//           "studyFirstSubmitQcDate": "2010-05-18",
//           "studyFirstPostDateStruct": {
//             "date": "2010-05-20",
//             "type": "ESTIMATED"
//           },
//           "resultsFirstSubmitDate": "2019-05-01",
//           "resultsFirstSubmitQcDate": "2019-06-24",
//           "resultsFirstPostDateStruct": {
//             "date": "2019-07-02",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2019-08-27",
//           "lastUpdatePostDateStruct": {
//             "date": "2019-09-10",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "SPONSOR"
//           },
//           "leadSponsor": {
//             "name": "Northwestern University",
//             "class": "OTHER"
//           },
//           "collaborators": [
//             {
//               "name": "National Cancer Institute (NCI)",
//               "class": "NIH"
//             }
//           ]
//         },
//         "oversightModule": {
//           "oversightHasDmc": true,
//           "isFdaRegulatedDrug": true,
//           "isFdaRegulatedDevice": false
//         },
//         "descriptionModule": {
//           "briefSummary": "RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\n\nPURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.",
//           "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. Determine whether genistein treatment will decrease the number of circulating prostate cells (CPCs) in the peripheral blood as measured by qRT-PCR for PSA performed on RNA extracted from peripheral blood mononuclear cells (PBMNCs).\n\nSECONDARY OBJECTIVES:\n\nI. Determine the natural history of circulating prostate cells (CPCs) in a cohort of subjects prior to and post radical prostatectomy.\n\nII. Compare the measurement of PSA between three separate methods: in CPCs by qRT-PCR, in serum by the standard clinical chemistry assay (i.e., ELISA), and in plasma and serum by the nano-PSA assay.\n\nIII. Measure the effect of genistein on gene and protein expression in prostate tissue by qRT-PCR and immunohistochemistry, respectively, for the following genes and their respective protein products: HSP27, MMP-2, ALK-2, BASP1, and HCF2.\n\nOUTLINE:\n\nPatients are randomized to 1 of 2 treatment arms.\n\nARM I: Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nARM II: Patients receive oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nAll patients undergo radical prostatectomy at least 2 weeks, but not more than 3 months following the start of therapy.\n\nAfter completion of study treatment, patients are followed at 1, 6, and 12 months."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Adenocarcinoma of the Prostate",
//             "Recurrent Prostate Cancer",
//             "Stage I Prostate Cancer",
//             "Stage II Prostate Cancer",
//             "Stage III Prostate Cancer"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "PHASE2"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "PARALLEL",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "DOUBLE",
//               "whoMasked": [
//                 "PARTICIPANT",
//                 "INVESTIGATOR"
//               ]
//             }
//           },
//           "enrollmentInfo": {
//             "count": 12,
//             "type": "ACTUAL"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "Arm I",
//               "type": "EXPERIMENTAL",
//               "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.",
//               "interventionNames": [
//                 "Dietary Supplement: genistein",
//                 "Procedure: therapeutic conventional surgery"
//               ]
//             },
//             {
//               "label": "Arm II",
//               "type": "PLACEBO_COMPARATOR",
//               "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.",
//               "interventionNames": [
//                 "Other: placebo",
//                 "Procedure: therapeutic conventional surgery"
//               ]
//             }
//           ],
//           "interventions": [
//             {
//               "type": "DIETARY_SUPPLEMENT",
//               "name": "genistein",
//               "description": "Given orally",
//               "armGroupLabels": [
//                 "Arm I"
//               ],
//               "otherNames": [
//                 "CI 75610",
//                 "Genestein",
//                 "genisteol",
//                 "genisterin",
//                 "prunetol",
//                 "sophoricol"
//               ]
//             },
//             {
//               "type": "OTHER",
//               "name": "placebo",
//               "description": "Given orally",
//               "armGroupLabels": [
//                 "Arm II"
//               ],
//               "otherNames": [
//                 "PLCB"
//               ]
//             },
//             {
//               "type": "PROCEDURE",
//               "name": "therapeutic conventional surgery",
//               "description": "Radical prostatectomy for treatment of prostate cancer",
//               "armGroupLabels": [
//                 "Arm I",
//                 "Arm II"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs",
//               "description": "Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.",
//               "timeFrame": "At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery"
//             }
//           ],
//           "secondaryOutcomes": [
//             {
//               "measure": "Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy",
//               "description": "Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.",
//               "timeFrame": "At baseline, 1 and 12 months after surgery"
//             },
//             {
//               "measure": "Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue",
//               "description": "At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.",
//               "timeFrame": "At baseline and at time of surgery"
//             },
//             {
//               "measure": "Measurement of PSA in Serum and Plasma by Nanotechnology",
//               "description": "Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.",
//               "timeFrame": "At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion\n\n* Participants must have a pathologic diagnosis of prostate cancer within the past 6 months, have clinical stage T1-3 disease, PSA \\>= 10, Gleason score \\>= 8, and have elected to undergo radical prostatectomy; those found to have detectable circulating prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to proceed onto the treatment phase of the protocol; pathology slides used for diagnosis will be submitted to the SPORE tissue pathology core for review\n* ECOG performance status 0-1\n* Hemoglobin \\> 9.0gm/dl\n* Platelets \\>= 100 K/uL\n* ANC \\> 1000/uL\n* AST (SGOT)/ALT (SGPT) \\< 3X upper limit of normal\n* Creatinine \\< 2.0 mg/dl\n* Total bilirubin \\< 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)\n* Participants must agree not to take soy supplements\n* Ability to understand and the willingness to sign a written informed consent document\n* Willingness to take study agent for at least 2 weeks prior to radical prostatectomy\n\nExclusion\n\n* History of venous thrombosis within past year\n* Participants must not be receiving active therapy for neoplastic disorders (including hormone or radiation therapy for prostate cancer)\n* Participants may not be receiving any other investigational agents\n* Known soy intolerance\n* Medical conditions that, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained",
//           "healthyVolunteers": false,
//           "sex": "MALE",
//           "minimumAge": "18 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "overallOfficials": [
//             {
//               "name": "William Catalona",
//               "affiliation": "Northwestern University",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "Northwestern University",
//               "city": "Chicago",
//               "state": "Illinois",
//               "zip": "60611",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 41.85003,
//                 "lon": -87.65005
//               }
//             }
//           ]
//         }
//       },
//       "resultsSection": {
//         "participantFlowModule": {
//           "preAssignmentDetails": "Patients entered the study and were treated in a double blinded fashion with a ration of 2:1 Genistein:Placebo. Unblinding occured if it was medically necessary otherwise blinding was maintained until the time of data review.",
//           "recruitmentDetails": "The study opened on October 21, 2010 with an accrual goal of 30 patients with firs the patient enrolled March 3, 2011. The study was designed as a randomized blinded drug/placebo study but was amended to a single arm drug study and accrual reduced to 18. Study closed permanently on May 28, 2014 due to low accrual with 12 patients treated on study.",
//           "groups": [
//             {
//               "id": "FG000",
//               "title": "Arm I - Genistein",
//               "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//             },
//             {
//               "id": "FG001",
//               "title": "Arm II - Placebo",
//               "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//             }
//           ],
//           "periods": [
//             {
//               "title": "Overall Study",
//               "milestones": [
//                 {
//                   "type": "STARTED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "8"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "4"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Started 3 Months of Genistein/Placebo",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "8"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "4"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Prostatectomy or Radiation",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "8"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "4"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Completed 3 Months Genistein/Placebo",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "4"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "2"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "COMPLETED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "3"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "2"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "NOT COMPLETED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "5"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "2"
//                     }
//                   ]
//                 }
//               ],
//               "dropWithdraws": [
//                 {
//                   "type": "Progressive Disease",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "3"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "1"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Withdrawal by Subject",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "1"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "0"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Adverse Event",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "0"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "1"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Physician Decision",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "1"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "0"
//                     }
//                   ]
//                 }
//               ]
//             }
//           ]
//         },
//         "baselineCharacteristicsModule": {
//           "groups": [
//             {
//               "id": "BG000",
//               "title": "Arm I - Genistein",
//               "description": "Patients receive oral genistein or placebo once daily for 3 months beginning at least 2 weeks prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//             },
//             {
//               "id": "BG001",
//               "title": "Arm II - Placebo",
//               "description": "Patients receive oral genistein or placebo once daily for 3 months beginning at least 2 weeks prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//             },
//             {
//               "id": "BG002",
//               "title": "Total",
//               "description": "Total of all reporting groups"
//             }
//           ],
//           "denoms": [
//             {
//               "units": "Participants",
//               "counts": [
//                 {
//                   "groupId": "BG000",
//                   "value": "8"
//                 },
//                 {
//                   "groupId": "BG001",
//                   "value": "4"
//                 },
//                 {
//                   "groupId": "BG002",
//                   "value": "12"
//                 }
//               ]
//             }
//           ],
//           "measures": [
//             {
//               "title": "Age, Categorical",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "<=18 years",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Between 18 and 65 years",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "5"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "7"
//                         }
//                       ]
//                     },
//                     {
//                       "title": ">=65 years",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "5"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Sex: Female, Male",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Female",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Male",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "4"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "12"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Ethnicity (NIH/OMB)",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Hispanic or Latino",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "1"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Not Hispanic or Latino",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "11"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Unknown or Not Reported",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Race (NIH/OMB)",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "American Indian or Alaska Native",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Asian",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Native Hawaiian or Other Pacific Islander",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Black or African American",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "White",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "4"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "12"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "More than one race",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Unknown or Not Reported",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "0"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Region of Enrollment",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "title": "United States",
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "4"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "12"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             }
//           ]
//         },
//         "outcomeMeasuresModule": {
//           "outcomeMeasures": [
//             {
//               "type": "PRIMARY",
//               "title": "Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs",
//               "description": "Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.",
//               "populationDescription": "Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.",
//               "reportingStatus": "POSTED",
//               "timeFrame": "At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Arm I - Genistein",
//                   "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Arm II - Placebo",
//                   "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "0"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "0"
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "type": "SECONDARY",
//               "title": "Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy",
//               "description": "Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.",
//               "populationDescription": "Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.",
//               "reportingStatus": "POSTED",
//               "timeFrame": "At baseline, 1 and 12 months after surgery",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Arm I - Genistein",
//                   "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Arm II - Placebo",
//                   "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "0"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "0"
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "type": "SECONDARY",
//               "title": "Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue",
//               "description": "At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.",
//               "populationDescription": "Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.",
//               "reportingStatus": "POSTED",
//               "timeFrame": "At baseline and at time of surgery",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Arm I - Genistein",
//                   "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Arm II - Placebo",
//                   "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "0"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "0"
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "type": "SECONDARY",
//               "title": "Measurement of PSA in Serum and Plasma by Nanotechnology",
//               "description": "Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.",
//               "populationDescription": "Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.",
//               "reportingStatus": "POSTED",
//               "timeFrame": "At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Arm I - Genistein",
//                   "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Arm II - Placebo",
//                   "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "0"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "0"
//                     }
//                   ]
//                 }
//               ]
//             }
//           ]
//         },
//         "adverseEventsModule": {
//           "frequencyThreshold": "0",
//           "timeFrame": "Adverse Events assessed at the following timepoints for the study: at the start of treatment, at surgery or radiation, at clinic visits occurring 1-3 months post-surgery, or post-initiation of radiation therapy, or at 3 months for those not undergoing surgery or radiation, as well as at a 4 month telephone contact.",
//           "description": "Adverse events were collected by patient reports",
//           "eventGroups": [
//             {
//               "id": "EG000",
//               "title": "Arm I - Genistein",
//               "description": "Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nGenistein: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer",
//               "deathsNumAffected": 0,
//               "deathsNumAtRisk": 8,
//               "seriousNumAffected": 1,
//               "seriousNumAtRisk": 8,
//               "otherNumAffected": 2,
//               "otherNumAtRisk": 8
//             },
//             {
//               "id": "EG001",
//               "title": "Arm II - Placebo",
//               "description": "Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\n\nPlacebo: Given orally\n\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer",
//               "deathsNumAffected": 0,
//               "deathsNumAtRisk": 4,
//               "seriousNumAffected": 0,
//               "seriousNumAtRisk": 4,
//               "otherNumAffected": 1,
//               "otherNumAtRisk": 4
//             }
//           ],
//           "seriousEvents": [
//             {
//               "term": "Atrial Fibrillation",
//               "organSystem": "Cardiac disorders",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 1,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 0,
//                   "numAtRisk": 4
//                 }
//               ]
//             }
//           ],
//           "otherEvents": [
//             {
//               "term": "Pain in Extremity",
//               "organSystem": "Musculoskeletal and connective tissue disorders",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 0,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 1,
//                   "numAtRisk": 4
//                 }
//               ]
//             },
//             {
//               "term": "Dizziness",
//               "organSystem": "Nervous system disorders",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 0,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 1,
//                   "numAtRisk": 4
//                 }
//               ]
//             },
//             {
//               "term": "Large pimple",
//               "organSystem": "Skin and subcutaneous tissue disorders",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 0,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 1,
//                   "numAtRisk": 4
//                 }
//               ]
//             },
//             {
//               "term": "Emergency right inguinal repair",
//               "organSystem": "Surgical and medical procedures",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 1,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 0,
//                   "numAtRisk": 4
//                 }
//               ]
//             },
//             {
//               "term": "Atrial Fibrillation",
//               "organSystem": "Cardiac disorders",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 1,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 0,
//                   "numAtRisk": 4
//                 }
//               ]
//             },
//             {
//               "term": "INR Increased",
//               "organSystem": "Investigations",
//               "sourceVocabulary": "CTCAE (3.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numAffected": 1,
//                   "numAtRisk": 8
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numAffected": 0,
//                   "numAtRisk": 4
//                 }
//               ]
//             }
//           ]
//         },
//         "moreInfoModule": {
//           "limitationsAndCaveats": {
//             "description": "The study was closed by an internal safety and data monitoring committee due to slow accrual of the study."
//           },
//           "certainAgreement": {
//             "piSponsorEmployee": true
//           },
//           "pointOfContact": {
//             "title": "William Catalona, MD",
//             "organization": "Northwestern University",
//             "email": "WCatalona@nm.org",
//             "phone": "312-695-1301"
//           }
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D011471",
//               "term": "Prostatic Neoplasms"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D005834",
//               "term": "Genital Neoplasms, Male"
//             },
//             {
//               "id": "D014565",
//               "term": "Urogenital Neoplasms"
//             },
//             {
//               "id": "D009371",
//               "term": "Neoplasms by Site"
//             },
//             {
//               "id": "D009369",
//               "term": "Neoplasms"
//             },
//             {
//               "id": "D005832",
//               "term": "Genital Diseases, Male"
//             },
//             {
//               "id": "D000091662",
//               "term": "Genital Diseases"
//             },
//             {
//               "id": "D000091642",
//               "term": "Urogenital Diseases"
//             },
//             {
//               "id": "D011469",
//               "term": "Prostatic Diseases"
//             },
//             {
//               "id": "D052801",
//               "term": "Male Urogenital Diseases"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M14850",
//               "name": "Recurrence",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M3585",
//               "name": "Adenocarcinoma",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M14335",
//               "name": "Prostatic Neoplasms",
//               "asFound": "Prostate Cancer",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M8946",
//               "name": "Genital Neoplasms, Male",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M17315",
//               "name": "Urogenital Neoplasms",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M2876",
//               "name": "Genital Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M8944",
//               "name": "Genital Diseases, Male",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M2875",
//               "name": "Urogenital Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M14333",
//               "name": "Prostatic Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M27095",
//               "name": "Male Urogenital Diseases",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC23",
//               "name": "Symptoms and General Pathology"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             },
//             {
//               "abbrev": "BC04",
//               "name": "Neoplasms"
//             },
//             {
//               "abbrev": "BXS",
//               "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
//             }
//           ]
//         },
//         "interventionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D019833",
//               "term": "Genistein"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D016588",
//               "term": "Anticarcinogenic Agents"
//             },
//             {
//               "id": "D020011",
//               "term": "Protective Agents"
//             },
//             {
//               "id": "D045505",
//               "term": "Physiological Effects of Drugs"
//             },
//             {
//               "id": "D000970",
//               "term": "Antineoplastic Agents"
//             },
//             {
//               "id": "D047428",
//               "term": "Protein Kinase Inhibitors"
//             },
//             {
//               "id": "D004791",
//               "term": "Enzyme Inhibitors"
//             },
//             {
//               "id": "D045504",
//               "term": "Molecular Mechanisms of Pharmacological Action"
//             },
//             {
//               "id": "D048789",
//               "term": "Phytoestrogens"
//             },
//             {
//               "id": "D004968",
//               "term": "Estrogens, Non-Steroidal"
//             },
//             {
//               "id": "D004967",
//               "term": "Estrogens"
//             },
//             {
//               "id": "D006728",
//               "term": "Hormones"
//             },
//             {
//               "id": "D006730",
//               "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M21721",
//               "name": "Genistein",
//               "asFound": "Gastroscopy",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M21869",
//               "name": "Protective Agents",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M25820",
//               "name": "Protein Kinase Inhibitors",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7951",
//               "name": "Enzyme Inhibitors",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M25995",
//               "name": "Phytoestrogens",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M8116",
//               "name": "Estrogens",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M9789",
//               "name": "Hormones",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M9788",
//               "name": "Hormone Antagonists",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "ANeo",
//               "name": "Antineoplastic Agents"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             }
//           ]
//         }
//       },
//       "hasResults": true
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT03058679",
//           "orgStudyIdInfo": {
//             "id": "825907"
//           },
//           "organization": {
//             "fullName": "University of Pennsylvania",
//             "class": "OTHER"
//           },
//           "briefTitle": "Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease",
//           "officialTitle": "Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease",
//           "acronym": "DINE-CD"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2021-06",
//           "overallStatus": "COMPLETED",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2017-09-29",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2020-03-01",
//             "type": "ACTUAL"
//           },
//           "completionDateStruct": {
//             "date": "2020-03-01",
//             "type": "ACTUAL"
//           },
//           "studyFirstSubmitDate": "2017-02-16",
//           "studyFirstSubmitQcDate": "2017-02-16",
//           "studyFirstPostDateStruct": {
//             "date": "2017-02-23",
//             "type": "ACTUAL"
//           },
//           "resultsFirstSubmitDate": "2021-03-26",
//           "resultsFirstSubmitQcDate": "2021-06-30",
//           "resultsFirstPostDateStruct": {
//             "date": "2021-07-21",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2021-06-30",
//           "lastUpdatePostDateStruct": {
//             "date": "2021-07-21",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "SPONSOR"
//           },
//           "leadSponsor": {
//             "name": "University of Pennsylvania",
//             "class": "OTHER"
//           },
//           "collaborators": [
//             {
//               "name": "Patient-Centered Outcomes Research Institute",
//               "class": "OTHER"
//             },
//             {
//               "name": "Crohn's and Colitis Foundation",
//               "class": "OTHER"
//             },
//             {
//               "name": "University of North Carolina, Chapel Hill",
//               "class": "OTHER"
//             }
//           ]
//         },
//         "oversightModule": {
//           "oversightHasDmc": true,
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": false
//         },
//         "descriptionModule": {
//           "briefSummary": "This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and bowel inflammation that characterize this debilitating disease.",
//           "detailedDescription": "This study tested whether the SCD is superior to a MSD for managing symptoms and reducing inflammatory markers in patients with CD.\n\nThe study was designed to include 194 patients with CD who have 1) active symptoms defined by a short Crohn's Disease Activity Index (sCDAI) score \\>175. Although the initial plan was to also require that all patients have active inflammation documented by a fecal calprotectin (FCP) concentration \\>250mcg/g or high sensitivity C-reactive protein (CRP) \\>7 mg/L or ulceration of the small bowel and/or colon consistent with an SES-CD score \\>4 as documented in routine clinical practice within 4 weeks of screening, a decision was made early in the recruitment period to enroll all patients with CD with sCDAI\\>175 regardless of the results of the tests for inflammatory markers and to perform subgroup analyses of those with and without evidence of inflammation.\n\nEligible participants were randomly assigned to follow one of the diets in a 1:1 ratio. Participants were provided with 3 meals and 2 snacks each day for a period of 6 weeks. The meals and snacks were prepared by the food vendor, Healthy Chef Creations, and were delivered directly to the participant's home once per week. Participants in both groups were also provided with instructions on how to follow the diets on their own. Participants reported their symptoms through an electronic diary and provided stool samples for FCP measurement and blood for CRP measurement at weeks 0, 6 and 12. The primary and secondary outcomes were assessed at week 6. Following week 6, participants were able to pay out of pocket to purchase food from Healthy Chef Creations and/or could attempt to follow their assigned diet completely on their own. At week 12, in addition to the primary and secondary outcomes assessed again"
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Crohn Disease"
//           ],
//           "keywords": [
//             "diet",
//             "specific carbohydrate diet",
//             "Mediterranean style diet",
//             "randomized controlled trial"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "NA"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "PARALLEL",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "NONE"
//             }
//           },
//           "enrollmentInfo": {
//             "count": 197,
//             "type": "ACTUAL"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "Specific Carbohydrate Diet",
//               "type": "EXPERIMENTAL",
//               "description": "For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.",
//               "interventionNames": [
//                 "Other: Diet"
//               ]
//             },
//             {
//               "label": "Mediterranean Style Diet",
//               "type": "ACTIVE_COMPARATOR",
//               "description": "For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.",
//               "interventionNames": [
//                 "Other: Diet"
//               ]
//             }
//           ],
//           "interventions": [
//             {
//               "type": "OTHER",
//               "name": "Diet",
//               "description": "food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks",
//               "armGroupLabels": [
//                 "Mediterranean Style Diet",
//                 "Specific Carbohydrate Diet"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "Percentage of Participants That Achieved Symptomatic Remission at Week 6",
//               "description": "Assessed by Short Crohn's Disease Activity Index (sCDAI) - diarrhea, abdominal pain and general well being; sCDAI \\<150 in the absence of initiation or increase of any CD medications",
//               "timeFrame": "6 weeks"
//             },
//             {
//               "measure": "Reduction in Bowel Inflammation Among Those Whose Screening Fecal Calprotectin (FC) Was Greater Than 250g/g at Baseline and Who Had an FC Results at Both Baseline and Week 6",
//               "description": "reduction of calprotectin to less than 250 g/g and by greater than 50% from screening among those with screening FC \\>250 g/g",
//               "timeFrame": "6 weeks"
//             }
//           ],
//           "secondaryOutcomes": [
//             {
//               "measure": "Percentage of Participants That Reached Clinical Remission at Week 6",
//               "description": "Assessed by the CDAI - CDAI \\<150",
//               "timeFrame": "6 weeks"
//             },
//             {
//               "measure": "Percentage of Participants With a Reduction in Systemic Inflammation at Week 6",
//               "description": "reduction in high-sensitivity CRP (hsCRP) to \\<5 mg/L and \\>50% reduction from screening among those with screening hsCRP \\>5mg/L",
//               "timeFrame": "6 weeks"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria\n\n1. Age 18\n2. Documented diagnosis of Crohn's disease\n3. sCDAI score \\>175\n4. Documentation of receipt of a baseline stool sample by the data coordinating center and hsCRP.\n5. Access to a computer with internet and the ability to complete daily online surveys\n6. Capable of providing consent to participate\n7. Able to receive weekly food shipments delivered every Friday for 6 weeks\n\nExclusion Criteria\n\n1. Pregnancy\n2. sCDAI \\>400\n3. Hospitalized patients\n4. Anticipated need for surgery within 6 weeks of randomization\n5. Use of the Specific Carbohydrate Diet within 4 weeks of screening\n6. Start or change\\*\\*\\* dose of thiopurines (azathioprine and 6-MP), methotrexate, natalizumab, or vedolizumab within 12 weeks prior to screening\n7. Start or change\\*\\*\\* dose of anti-tumor necrosis factor (TNF) agents (including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi) or ustekinumab within 8 weeks prior to screening.\n8. Start or change in dose of any 5-aminosalicylic acid (5-ASA) medications within 2 weeks of screening.\n9. Start or change dose of corticosteroids within 1 week of screening or a dose \\>20mg/day prednisone or equivalent\\*\n10. Use of antibiotics (other than topical formulations) for any reason within 2 weeks prior to screening\n11. Known symptomatic intestinal stricture.\n12. Presence of an ostomy\n13. Baseline stool frequency \\>4 bowel movements/day when well\n14. BMI \\<16\n15. BMI 40\n16. Celiac disease\n17. Documented C difficile colitis within four weeks of screening\n18. Diabetes Mellitus requiring medication\n19. Albumin\\<2.0mg/dl, within 4 weeks of screening (if tested as part of routine clinical care)\n20. Known allergy to tree nuts or peanuts\n21. Other conditions that would be a contraindication to any of the study diets or preclude the participant from completing the study.\n22. Currently participating in another clinical trial of a drug to treat Inflammatory Bowel Disease (IBD) or a dietary therapy for any indication.\n\n    * Patients may continue these medications at stable dose for the first six weeks and budesonide may be used at any dose. After the 6th week in the study, patients may taper their steroid dose. The study will provide a recommended taper schedule.\n\n      * Loading/induction doses of biologic type medication will be considered a stable doses. \\*\\*\\*Exception for treatment failures: if a subject is determined to fail on any of the following standard lines of treatment at the treating investigator's discretion, subjects may screen for study intervention based upon the following wash out periods: 4 weeks for thiopurine and methotrexate and 8 weeks for natalizumab, vedolizumab, anti-TNF, or ustekinumab.",
//           "healthyVolunteers": false,
//           "sex": "ALL",
//           "minimumAge": "18 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "overallOfficials": [
//             {
//               "name": "James D Lewis, MD, MSCE",
//               "affiliation": "University of Pennsylvania",
//               "role": "PRINCIPAL_INVESTIGATOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "University of Arizona",
//               "city": "Tucson",
//               "state": "Arizona",
//               "zip": "85724",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 32.22174,
//                 "lon": -110.92648
//               }
//             },
//             {
//               "facility": "UCSF Colitis and Crohn's Disease Center",
//               "city": "San Francisco",
//               "state": "California",
//               "zip": "94115",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 37.77493,
//                 "lon": -122.41942
//               }
//             },
//             {
//               "facility": "University of Colorado Denver",
//               "city": "Denver",
//               "state": "Colorado",
//               "zip": "80204",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 39.73915,
//                 "lon": -104.9847
//               }
//             },
//             {
//               "facility": "Emory University",
//               "city": "Atlanta",
//               "state": "Georgia",
//               "zip": "30322",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 33.749,
//                 "lon": -84.38798
//               }
//             },
//             {
//               "facility": "Atlanta Gastroenterology",
//               "city": "Atlanta",
//               "state": "Georgia",
//               "zip": "30342",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 33.749,
//                 "lon": -84.38798
//               }
//             },
//             {
//               "facility": "University of Chicago",
//               "city": "Chicago",
//               "state": "Illinois",
//               "zip": "60614",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 41.85003,
//                 "lon": -87.65005
//               }
//             },
//             {
//               "facility": "NorthShore University HealthSystem",
//               "city": "Evanston",
//               "state": "Illinois",
//               "zip": "60201",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.04114,
//                 "lon": -87.69006
//               }
//             },
//             {
//               "facility": "Northwestern University",
//               "city": "Evanston",
//               "state": "Illinois",
//               "zip": "60208",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.04114,
//                 "lon": -87.69006
//               }
//             },
//             {
//               "facility": "Indiana University Health University Hospital",
//               "city": "Indianapolis",
//               "state": "Indiana",
//               "zip": "46202",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 39.76838,
//                 "lon": -86.15804
//               }
//             },
//             {
//               "facility": "The University of Louisville",
//               "city": "Louisville",
//               "state": "Kentucky",
//               "zip": "40202",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 38.25424,
//                 "lon": -85.75941
//               }
//             },
//             {
//               "facility": "University of Maryland Baltimore",
//               "city": "Baltimore",
//               "state": "Maryland",
//               "zip": "21201",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 39.29038,
//                 "lon": -76.61219
//               }
//             },
//             {
//               "facility": "Boston Children's Hospital",
//               "city": "Boston",
//               "state": "Massachusetts",
//               "zip": "02115",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.35843,
//                 "lon": -71.05977
//               }
//             },
//             {
//               "facility": "Clinical Research Institute of Michigan",
//               "city": "Chesterfield",
//               "state": "Michigan",
//               "zip": "48047",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.66281,
//                 "lon": -82.84242
//               }
//             },
//             {
//               "facility": "Troy Gastroenterology",
//               "city": "Troy",
//               "state": "Michigan",
//               "zip": "48092",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 42.60559,
//                 "lon": -83.14993
//               }
//             },
//             {
//               "facility": "The University of Minnesota",
//               "city": "Minneapolis",
//               "state": "Minnesota",
//               "zip": "55455",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 44.97997,
//                 "lon": -93.26384
//               }
//             },
//             {
//               "facility": "Minnesota Gastroenterology, P.A",
//               "city": "Plymouth",
//               "state": "Minnesota",
//               "zip": "55446",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 45.01052,
//                 "lon": -93.45551
//               }
//             },
//             {
//               "facility": "Mayo Clinic - Rochester",
//               "city": "Rochester",
//               "state": "Minnesota",
//               "zip": "55905",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 44.02163,
//                 "lon": -92.4699
//               }
//             },
//             {
//               "facility": "Dartmouth-Hitchcock Medical Center",
//               "city": "Lebanon",
//               "state": "New Hampshire",
//               "zip": "03756",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 43.64229,
//                 "lon": -72.25176
//               }
//             },
//             {
//               "facility": "NYU Langone Medical Center",
//               "city": "New York",
//               "state": "New York",
//               "zip": "10016",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 40.71427,
//                 "lon": -74.00597
//               }
//             },
//             {
//               "facility": "Weill Cornell - NewYork Presbyterian",
//               "city": "New York",
//               "state": "New York",
//               "zip": "10021",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 40.71427,
//                 "lon": -74.00597
//               }
//             },
//             {
//               "facility": "Icahn School of Medicine at Mount Sinai",
//               "city": "New York",
//               "state": "New York",
//               "zip": "10029",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 40.71427,
//                 "lon": -74.00597
//               }
//             },
//             {
//               "facility": "Lenox Hill Hospital",
//               "city": "New York",
//               "state": "New York",
//               "zip": "10075",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 40.71427,
//                 "lon": -74.00597
//               }
//             },
//             {
//               "facility": "The University of North Carolina",
//               "city": "Chapel Hill",
//               "state": "North Carolina",
//               "zip": "27599",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 35.9132,
//                 "lon": -79.05584
//               }
//             },
//             {
//               "facility": "Atrium Health (formerly Carolinas HealthCare System)",
//               "city": "Charlotte",
//               "state": "North Carolina",
//               "zip": "28203",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 35.22709,
//                 "lon": -80.84313
//               }
//             },
//             {
//               "facility": "Wake Forest Baptist Medical Center",
//               "city": "Winston-Salem",
//               "state": "North Carolina",
//               "zip": "27157",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 36.09986,
//                 "lon": -80.24422
//               }
//             },
//             {
//               "facility": "University of Cincinnati",
//               "city": "Cincinnati",
//               "state": "Ohio",
//               "zip": "45267",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 39.12713,
//                 "lon": -84.51435
//               }
//             },
//             {
//               "facility": "University Hospitals Cleveland Medical Center",
//               "city": "Cleveland",
//               "state": "Ohio",
//               "zip": "44106",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 41.4995,
//                 "lon": -81.69541
//               }
//             },
//             {
//               "facility": "Ohio State University - Wexner Medical Center",
//               "city": "Columbus",
//               "state": "Ohio",
//               "zip": "43210",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 39.96118,
//                 "lon": -82.99879
//               }
//             },
//             {
//               "facility": "University of Pennsylvania",
//               "city": "Philadelphia",
//               "state": "Pennsylvania",
//               "zip": "19104",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 39.95233,
//                 "lon": -75.16379
//               }
//             },
//             {
//               "facility": "University of Pittsburgh Medical Center",
//               "city": "Pittsburgh",
//               "state": "Pennsylvania",
//               "zip": "15213",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 40.44062,
//                 "lon": -79.99589
//               }
//             },
//             {
//               "facility": "Lifespan Health System",
//               "city": "Providence",
//               "state": "Rhode Island",
//               "zip": "02903",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 41.82399,
//                 "lon": -71.41283
//               }
//             },
//             {
//               "facility": "Vanderbilt University Medical Center",
//               "city": "Nashville",
//               "state": "Tennessee",
//               "zip": "37232",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 36.16589,
//                 "lon": -86.78444
//               }
//             },
//             {
//               "facility": "University of Utah",
//               "city": "Salt Lake City",
//               "state": "Utah",
//               "zip": "84112",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 40.76078,
//                 "lon": -111.89105
//               }
//             },
//             {
//               "facility": "Virginia Mason Medical Center",
//               "city": "Seattle",
//               "state": "Washington",
//               "zip": "98101",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 47.60621,
//                 "lon": -122.33207
//               }
//             },
//             {
//               "facility": "University of Wisconsin-Madison",
//               "city": "Madison",
//               "state": "Wisconsin",
//               "zip": "53706",
//               "country": "United States",
//               "geoPoint": {
//                 "lat": 43.07305,
//                 "lon": -89.40123
//               }
//             }
//           ]
//         },
//         "referencesModule": {
//           "references": [
//             {
//               "pmid": "34052278",
//               "type": "DERIVED",
//               "citation": "Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson JS, Suskind DL, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen BL, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H; DINE-CD Study Group. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. Gastroenterology. 2021 Sep;161(3):837-852.e9. doi: 10.1053/j.gastro.2021.05.047. Epub 2021 May 27. Erratum In: Gastroenterology. 2022 Nov;163(5):1473. doi: 10.1053/j.gastro.2022.07.058."
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "NO"
//         }
//       },
//       "resultsSection": {
//         "participantFlowModule": {
//           "preAssignmentDetails": "There were 3 main reasons that participants who consented to the study were not randomized. The majority did not meet eligibility criteria. A small number withdrew or were lost to follow-up",
//           "recruitmentDetails": "The study was conducted in 33 clinical sites across the United States. Enrollment in the trial occurred between September 29, 2017 and October 8, 2019.",
//           "groups": [
//             {
//               "id": "FG000",
//               "title": "Specific Carbohydrate Diet",
//               "description": "Diet: food for the diet will be provided to the participants for 6 weeks"
//             },
//             {
//               "id": "FG001",
//               "title": "Mediterranean Style Diet",
//               "description": "Diet: food for the diet will be provided to the participants for 6 weeks"
//             }
//           ],
//           "periods": [
//             {
//               "title": "Baseline to Week 6",
//               "milestones": [
//                 {
//                   "type": "STARTED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "comment": "3 randomized to SCD withdrew before starting diet;2 randomized pts w/ baseline sCDAI\\<150 excluded.",
//                       "numSubjects": "99"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "comment": "Due to an error 1 participant was randomized with a baseline sCDAI\\<150. This pt was excluded.",
//                       "numSubjects": "92"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "COMPLETED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "81"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "77"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "NOT COMPLETED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "18"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "15"
//                     }
//                   ]
//                 }
//               ],
//               "dropWithdraws": [
//                 {
//                   "type": "Lost to Follow-up",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "3"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "2"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Change in Crohn's disease medication",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "4"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "2"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Adverse Event",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "6"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "6"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Withdrawal by Subject",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "4"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "3"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Difficulty following the diet",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "0"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "2"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Physician Decision",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "1"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "0"
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Week 6 to Week 12",
//               "milestones": [
//                 {
//                   "type": "STARTED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "81"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "77"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "COMPLETED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "61"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "60"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "NOT COMPLETED",
//                   "achievements": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "20"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "17"
//                     }
//                   ]
//                 }
//               ],
//               "dropWithdraws": [
//                 {
//                   "type": "Change in medication",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "5"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "7"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Adverse Event",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "4"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "3"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Withdrawal by Subject",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "9"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "4"
//                     }
//                   ]
//                 },
//                 {
//                   "type": "Difficulty following the assigned diet",
//                   "reasons": [
//                     {
//                       "groupId": "FG000",
//                       "numSubjects": "2"
//                     },
//                     {
//                       "groupId": "FG001",
//                       "numSubjects": "3"
//                     }
//                   ]
//                 }
//               ]
//             }
//           ]
//         },
//         "baselineCharacteristicsModule": {
//           "groups": [
//             {
//               "id": "BG000",
//               "title": "Mediterranean Style Diet",
//               "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//             },
//             {
//               "id": "BG001",
//               "title": "Specific Carbohydrate Diet",
//               "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//             },
//             {
//               "id": "BG002",
//               "title": "Total",
//               "description": "Total of all reporting groups"
//             }
//           ],
//           "denoms": [
//             {
//               "units": "Participants",
//               "counts": [
//                 {
//                   "groupId": "BG000",
//                   "value": "92"
//                 },
//                 {
//                   "groupId": "BG001",
//                   "value": "99"
//                 },
//                 {
//                   "groupId": "BG002",
//                   "value": "191"
//                 }
//               ]
//             }
//           ],
//           "measures": [
//             {
//               "title": "Age, Continuous",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "years",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "37.0",
//                           "lowerLimit": "29.5",
//                           "upperLimit": "53.0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "36.0",
//                           "lowerLimit": "27.0",
//                           "upperLimit": "46.0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "37",
//                           "lowerLimit": "28.0",
//                           "upperLimit": "50.0"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Sex: Female, Male",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Female",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "63"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "58"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "121"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Male",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "29"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "41"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "70"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Ethnicity (NIH/OMB)",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Hispanic or Latino",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "4"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "4"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "8"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Not Hispanic or Latino",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "88"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "92"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "180"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Unknown or Not Reported",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "3"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Race/Ethnicity, Customized",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Asian",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Black",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "5"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "7"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Multiracial",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Other",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "4"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Unknown",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "White",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "86"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "88"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "174"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Body Mass Index (BMI)",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "kg/m2",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "25.1",
//                           "lowerLimit": "21.3",
//                           "upperLimit": "29.9"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "25.6",
//                           "lowerLimit": "22.5",
//                           "upperLimit": "29.0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "25.3",
//                           "lowerLimit": "21.8",
//                           "upperLimit": "29.5"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Smoking status",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Never",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "68"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "79"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "147"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Past",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "21"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "20"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "41"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Current",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "3"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Years since CD diagnosis",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "years",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "10",
//                           "lowerLimit": "5",
//                           "upperLimit": "21"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "10",
//                           "lowerLimit": "3",
//                           "upperLimit": "16"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "10",
//                           "lowerLimit": "4",
//                           "upperLimit": "17"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "CD behavior",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Non-stricturing, nonpenetrating",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "56"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "60"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "116"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Stricturing",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "19"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "17"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "36"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Penetrating",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "9"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "13"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "22"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Stricturing and penetrating",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "9"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "17"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Crohn's disease distribution",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Ileum alone",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "22"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "30"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "52"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Colon alone",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "17"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "13"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "30"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Ileum and Colon",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "53"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "55"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "108"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Missing",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "1"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "History of perianal fistula",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "24"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "20"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "44"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "History of intestinal surgery",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "34"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "29"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "63"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Current use of any biologic",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "55"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "53"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "108"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Current use of immunomodulators",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "11"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "11"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "22"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Current use of oral 5-ASA",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "6"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "15"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "21"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Current use of rectal 5 ASA",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "3"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Current use of oral steroids",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "3"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "11"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "14"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Current use of rectal steroids",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "3"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Number of prior anti-TNF medications",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "0",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "28"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "34"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "62"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "1",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "22"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "29"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "51"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "2",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "32"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "26"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "58"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "3",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "9"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "9"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "18"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "4",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Prior ustekinumab",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "22"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "23"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "45"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Prior vedolizumab",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "27"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "22"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "49"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "hsCRP mg/L",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "mg/L",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "2.5",
//                           "lowerLimit": "1.2",
//                           "upperLimit": "6.2"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "3.2",
//                           "lowerLimit": "1.4",
//                           "upperLimit": "8.1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2.9",
//                           "lowerLimit": "1.4",
//                           "upperLimit": "7.5"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "hsCRP >5 mg/L",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "28"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "37"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "65"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "fecal calprotectin (FC) ug/g",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "ug/g",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "40.0",
//                           "lowerLimit": "16.0",
//                           "upperLimit": "185.0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "107.5",
//                           "lowerLimit": "16.0",
//                           "upperLimit": "223.0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "70",
//                           "lowerLimit": "16.0",
//                           "upperLimit": "194.0"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "fecal calprotectin (FC) >250 ug/g",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "13"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "23"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "36"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Inflammation on colonoscopy",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "Not performed",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "80"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "89"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "169"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Yes",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "8"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "16"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Probably",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "1"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Probably not",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "No",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "2"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "3"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "FC>250 ug/g or hsCRP>5 mg/L or definite inflammation on colonoscopy",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "38"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "50"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "88"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "sCDAI (median, Q1-Q3)",
//               "description": "Short Crohn's Disease Activity Index. This is a method to measure Crohn's disease patient's symptoms using only a questionnaire,which can be completed without an office visit or lab work. The variables included in the short CDAI are abdominal pain, diarrhea frequency, and general well-being. The higher the score, the worse the disease activity. The sCDAI uses the same scale as the full CDAI, such that scores,\\<150 define remission, 150 to 219 mild activity, 220 to450 moderate activity, and.450 severe activity. The total score is reported.",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "units on a scale",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "217.7",
//                           "lowerLimit": "195.7",
//                           "upperLimit": "247.0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "226.0",
//                           "lowerLimit": "197.0",
//                           "upperLimit": "263.8"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "223.0",
//                           "lowerLimit": "195.7",
//                           "upperLimit": "259.6"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "CDAI (median, Q1-Q3)",
//               "description": "The Crohn's Disease Activity Index - CDAI scores range from 0 to 600. A score of less than 150 denotes relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. The higher the score, the worse the disease activity.\n\nThis index uses the following variables to determine a score: number of stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used in the previous 7 days, abdominal mass felt on palpation, hematocrit, and body weight",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "units on a scale",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "206.8",
//                           "lowerLimit": "179.3",
//                           "upperLimit": "247.0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "210.0",
//                           "lowerLimit": "169.8",
//                           "upperLimit": "246.2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "209.5",
//                           "lowerLimit": "171.5",
//                           "upperLimit": "246.2"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Short IBDQ (median, Q1-Q3)",
//               "description": "The SIBDQ is a 10-item health-related quality of life (HRQOL) questionnaire validated for use in CD patients. It assesses physical, social, and emotional status and is scored on a 7-point Likert scale from 1 (severe problem) to 7 (no problems at all). Scores for each question are summed to provide a total score. The total score is reported. The absolute score ranges from 10 (poor HRQOL) to 70 (optimum HRQOL).",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "units on a scale",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "38.0",
//                           "lowerLimit": "33.0",
//                           "upperLimit": "44.0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "40.0",
//                           "lowerLimit": "33.0",
//                           "upperLimit": "45.0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "39.0",
//                           "lowerLimit": "33.0",
//                           "upperLimit": "45.0"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "PROMIS measures (median, Q1-Q3)",
//               "description": "Patient-Reported Outcomes Measurement Information System (PROMIS)- set of person-centered measures that evaluate and monitor health status. All assessments are for the last 7 days. To calculate a total raw score, each item is scored on a scale of 1-5. If the form has 7 items, the lowest possible raw score is 7 and the highest possible raw score is 35. Raw scores are then translated into T scores. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. T-scores are reported. Higher T-scores denote worse outcomes.",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "units on a scale",
//               "classes": [
//                 {
//                   "title": "Fatigue",
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "60.4",
//                           "lowerLimit": "55.9",
//                           "upperLimit": "65.9"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "58.9",
//                           "lowerLimit": "54.8",
//                           "upperLimit": "65.6"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "59.6",
//                           "lowerLimit": "55.0",
//                           "upperLimit": "65.8"
//                         }
//                       ]
//                     }
//                   ]
//                 },
//                 {
//                   "title": "Pain interference",
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "60.1",
//                           "lowerLimit": "55.7",
//                           "upperLimit": "63.8"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "61.3",
//                           "lowerLimit": "55.7",
//                           "upperLimit": "63.6"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "61.2",
//                           "lowerLimit": "55.7",
//                           "upperLimit": "63.7"
//                         }
//                       ]
//                     }
//                   ]
//                 },
//                 {
//                   "title": "Sleep disturbance",
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "57.3",
//                           "lowerLimit": "51.4",
//                           "upperLimit": "62.1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "54.5",
//                           "lowerLimit": "49.4",
//                           "upperLimit": "60.2"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "56.0",
//                           "lowerLimit": "50.9",
//                           "upperLimit": "61.4"
//                         }
//                       ]
//                     }
//                   ]
//                 },
//                 {
//                   "title": "Social isolation",
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "48.4",
//                           "lowerLimit": "41.0",
//                           "upperLimit": "56.1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "47.2",
//                           "lowerLimit": "34.8",
//                           "upperLimit": "53.8"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "47.9",
//                           "lowerLimit": "34.8",
//                           "upperLimit": "54.5"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "Inflammatory back pain screen",
//               "description": "This self-reported survey assessed five criteria defining possible inflammatory back pain:(1) improvement with exercise (2) pain at night (3) insidious onset (4) age at onset \\<40 years and (5) no improvement with rest. The higher the score the more likely the person had inflammatory back pain.",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "title": "0",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "30"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "40"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "70"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "1-3",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "39"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "40"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "79"
//                         }
//                       ]
//                     },
//                     {
//                       "title": ">3",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "22"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "18"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "40"
//                         }
//                       ]
//                     },
//                     {
//                       "title": "Missing",
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "2"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "title": "AMeD Score",
//               "description": "Alternate Mediterranean Diet Score - Participants completed a 24-hour dietary recall at baseline, during week 6 and during week 12. These data were used to compute the Alternate Mediterranean Diet Score (AMeD) where a higher score implies greater consistency with a Mediterranean diet. AMeD scores range from 0 (minimal adherence) to 9 (maximal adherence).",
//               "paramType": "MEDIAN",
//               "dispersionType": "INTER_QUARTILE_RANGE",
//               "unitOfMeasure": "units on a scale",
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "BG000",
//                           "value": "3.0",
//                           "lowerLimit": "1.0",
//                           "upperLimit": "4.0"
//                         },
//                         {
//                           "groupId": "BG001",
//                           "value": "2.0",
//                           "lowerLimit": "1.0",
//                           "upperLimit": "3.0"
//                         },
//                         {
//                           "groupId": "BG002",
//                           "value": "3.0",
//                           "lowerLimit": "2.0",
//                           "upperLimit": "4.0"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             }
//           ]
//         },
//         "outcomeMeasuresModule": {
//           "outcomeMeasures": [
//             {
//               "type": "PRIMARY",
//               "title": "Percentage of Participants That Achieved Symptomatic Remission at Week 6",
//               "description": "Assessed by Short Crohn's Disease Activity Index (sCDAI) - diarrhea, abdominal pain and general well being; sCDAI \\<150 in the absence of initiation or increase of any CD medications",
//               "populationDescription": "percentage of participants who achieved symptomatic remission at week 6",
//               "reportingStatus": "POSTED",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "timeFrame": "6 weeks",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Mediterranean Style Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Specific Carbohydrate Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "92"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "99"
//                     }
//                   ]
//                 }
//               ],
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "OG000",
//                           "value": "40"
//                         },
//                         {
//                           "groupId": "OG001",
//                           "value": "46"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "type": "PRIMARY",
//               "title": "Reduction in Bowel Inflammation Among Those Whose Screening Fecal Calprotectin (FC) Was Greater Than 250g/g at Baseline and Who Had an FC Results at Both Baseline and Week 6",
//               "description": "reduction of calprotectin to less than 250 g/g and by greater than 50% from screening among those with screening FC \\>250 g/g",
//               "populationDescription": "This measure includes only those whose screening fecal calprotectin (FC) was greater than 250g/g at baseline and who had an FC results at both baseline and week 6",
//               "reportingStatus": "POSTED",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "timeFrame": "6 weeks",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Mediterranean Style Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Specific Carbohydrate Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "13"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "23"
//                     }
//                   ]
//                 }
//               ],
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "OG000",
//                           "value": "4"
//                         },
//                         {
//                           "groupId": "OG001",
//                           "value": "8"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "type": "SECONDARY",
//               "title": "Percentage of Participants That Reached Clinical Remission at Week 6",
//               "description": "Assessed by the CDAI - CDAI \\<150",
//               "reportingStatus": "POSTED",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "timeFrame": "6 weeks",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Mediterranean Style Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Specific Carbohydrate Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "92"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "99"
//                     }
//                   ]
//                 }
//               ],
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "OG000",
//                           "value": "44"
//                         },
//                         {
//                           "groupId": "OG001",
//                           "value": "48"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             },
//             {
//               "type": "SECONDARY",
//               "title": "Percentage of Participants With a Reduction in Systemic Inflammation at Week 6",
//               "description": "reduction in high-sensitivity CRP (hsCRP) to \\<5 mg/L and \\>50% reduction from screening among those with screening hsCRP \\>5mg/L",
//               "populationDescription": "This measure includes only those that had a screening hsCRP \\> 5mg/L and had hsCRP measured at both screening and at week 6",
//               "reportingStatus": "POSTED",
//               "paramType": "COUNT_OF_PARTICIPANTS",
//               "unitOfMeasure": "Participants",
//               "timeFrame": "6 weeks",
//               "groups": [
//                 {
//                   "id": "OG000",
//                   "title": "Mediterranean Style Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 },
//                 {
//                   "id": "OG001",
//                   "title": "Specific Carbohydrate Diet",
//                   "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks"
//                 }
//               ],
//               "denoms": [
//                 {
//                   "units": "Participants",
//                   "counts": [
//                     {
//                       "groupId": "OG000",
//                       "value": "28"
//                     },
//                     {
//                       "groupId": "OG001",
//                       "value": "37"
//                     }
//                   ]
//                 }
//               ],
//               "classes": [
//                 {
//                   "categories": [
//                     {
//                       "measurements": [
//                         {
//                           "groupId": "OG000",
//                           "value": "1"
//                         },
//                         {
//                           "groupId": "OG001",
//                           "value": "2"
//                         }
//                       ]
//                     }
//                   ]
//                 }
//               ]
//             }
//           ]
//         },
//         "adverseEventsModule": {
//           "frequencyThreshold": "5",
//           "timeFrame": "AEs were recorded at each study contact from screening visit to a participant's end of study visit. For participants that completed the study, AEs were assessed at screening, baseline, wk 6 and week 12. Among participants who withdrew early from the study, AEs were assessed at the above named timepoints until the time of withdraw. The clinical course of each AE was followed until resolution, stabilization, or until it was determined that study intervention or participation was not the cause.",
//           "description": "As per the DINE-CD protocol, allergic reaction to a component of the food, intolerance of the food other than allergic reaction, worsening of CD and worsening of extraintestinal manifestations of CD was considered expected. AEs were included for all randomized participants who started the diet with the exception of 3 participant who were randomized in error with an sCDAI \\<150 (as noted in the participant flow).",
//           "eventGroups": [
//             {
//               "id": "EG000",
//               "title": "Mediterranean Style Diet",
//               "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks",
//               "deathsNumAffected": 0,
//               "deathsNumAtRisk": 92,
//               "seriousNumAffected": 5,
//               "seriousNumAtRisk": 92,
//               "otherNumAffected": 18,
//               "otherNumAtRisk": 92
//             },
//             {
//               "id": "EG001",
//               "title": "Specific Carbohydrate Diet",
//               "description": "Diet: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks",
//               "deathsNumAffected": 0,
//               "deathsNumAtRisk": 99,
//               "seriousNumAffected": 3,
//               "seriousNumAtRisk": 99,
//               "otherNumAffected": 19,
//               "otherNumAtRisk": 99
//             }
//           ],
//           "seriousEvents": [
//             {
//               "term": "Small intestinal obstruction",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 1,
//                   "numAffected": 1,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 1,
//                   "numAffected": 1,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Abdominal pain",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 3,
//                   "numAffected": 3,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 3,
//                   "numAffected": 1,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Worsening of Crohn's disease",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 0,
//                   "numAffected": 0,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 2,
//                   "numAffected": 2,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Rectal hemorrhage",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 1,
//                   "numAffected": 1,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 0,
//                   "numAffected": 0,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Diarrhea",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 1,
//                   "numAffected": 1,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 0,
//                   "numAffected": 0,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Nausea",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 1,
//                   "numAffected": 1,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 0,
//                   "numAffected": 0,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Vomiting",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 1,
//                   "numAffected": 1,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 0,
//                   "numAffected": 0,
//                   "numAtRisk": 99
//                 }
//               ]
//             }
//           ],
//           "otherEvents": [
//             {
//               "term": "Abdominal pain",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 14,
//                   "numAffected": 13,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 11,
//                   "numAffected": 10,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Diarrhea",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 7,
//                   "numAffected": 7,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 5,
//                   "numAffected": 5,
//                   "numAtRisk": 99
//                 }
//               ]
//             },
//             {
//               "term": "Gastrointestingal disorders other - Worsening of Crohn's disease symptons",
//               "organSystem": "Gastrointestinal disorders",
//               "sourceVocabulary": "CTCAE (4.0)",
//               "assessmentType": "SYSTEMATIC_ASSESSMENT",
//               "stats": [
//                 {
//                   "groupId": "EG000",
//                   "numEvents": 4,
//                   "numAffected": 4,
//                   "numAtRisk": 92
//                 },
//                 {
//                   "groupId": "EG001",
//                   "numEvents": 7,
//                   "numAffected": 6,
//                   "numAtRisk": 99
//                 }
//               ]
//             }
//           ]
//         },
//         "moreInfoModule": {
//           "certainAgreement": {
//             "piSponsorEmployee": false,
//             "restrictiveAgreement": false
//           },
//           "pointOfContact": {
//             "title": "Dr. James D. Lewis",
//             "organization": "University of Pennsylvania",
//             "email": "lewisjd@pennmedicine.upenn.edu",
//             "phone": "215-573-5137"
//           }
//         }
//       },
//       "documentSection": {
//         "largeDocumentModule": {
//           "largeDocs": [
//             {
//               "typeAbbrev": "Prot_SAP",
//               "hasProtocol": true,
//               "hasSap": true,
//               "hasIcf": false,
//               "label": "Study Protocol and Statistical Analysis Plan",
//               "date": "2019-04-10",
//               "uploadDate": "2020-12-23T10:06",
//               "filename": "Prot_SAP_000.pdf",
//               "size": 1727953
//             }
//           ]
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D003424",
//               "term": "Crohn Disease"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D015212",
//               "term": "Inflammatory Bowel Diseases"
//             },
//             {
//               "id": "D005759",
//               "term": "Gastroenteritis"
//             },
//             {
//               "id": "D005767",
//               "term": "Gastrointestinal Diseases"
//             },
//             {
//               "id": "D004066",
//               "term": "Digestive System Diseases"
//             },
//             {
//               "id": "D007410",
//               "term": "Intestinal Diseases"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M6638",
//               "name": "Crohn Disease",
//               "asFound": "Crohn's Disease",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M17917",
//               "name": "Inflammatory Bowel Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M10444",
//               "name": "Intestinal Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M8875",
//               "name": "Gastroenteritis",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M8883",
//               "name": "Gastrointestinal Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M7255",
//               "name": "Digestive System Diseases",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC06",
//               "name": "Digestive System Diseases"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             }
//           ]
//         }
//       },
//       "hasResults": true
//     },
//     {
//       "protocolSection": {
//         "identificationModule": {
//           "nctId": "NCT05531279",
//           "orgStudyIdInfo": {
//             "id": "IIT2021022-EC-1"
//           },
//           "organization": {
//             "fullName": "Institute of Hematology & Blood Diseases Hospital, China",
//             "class": "OTHER"
//           },
//           "briefTitle": "A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency",
//           "officialTitle": "A Randomized,Open-label Dose-discovery Study of PEG-rhG-CSF and rhG-CSF in the Adjuvant Therapy of Aplastic Anemia Granulocyte Deficiency"
//         },
//         "statusModule": {
//           "statusVerifiedDate": "2022-09",
//           "overallStatus": "RECRUITING",
//           "expandedAccessInfo": {
//             "hasExpandedAccess": false
//           },
//           "startDateStruct": {
//             "date": "2022-06-05",
//             "type": "ACTUAL"
//           },
//           "primaryCompletionDateStruct": {
//             "date": "2025-06-05",
//             "type": "ESTIMATED"
//           },
//           "completionDateStruct": {
//             "date": "2026-01-05",
//             "type": "ESTIMATED"
//           },
//           "studyFirstSubmitDate": "2022-09-02",
//           "studyFirstSubmitQcDate": "2022-09-02",
//           "studyFirstPostDateStruct": {
//             "date": "2022-09-07",
//             "type": "ACTUAL"
//           },
//           "lastUpdateSubmitDate": "2022-09-22",
//           "lastUpdatePostDateStruct": {
//             "date": "2022-09-26",
//             "type": "ACTUAL"
//           }
//         },
//         "sponsorCollaboratorsModule": {
//           "responsibleParty": {
//             "type": "SPONSOR"
//           },
//           "leadSponsor": {
//             "name": "Institute of Hematology & Blood Diseases Hospital, China",
//             "class": "OTHER"
//           }
//         },
//         "oversightModule": {
//           "isFdaRegulatedDrug": false,
//           "isFdaRegulatedDevice": false
//         },
//         "descriptionModule": {
//           "briefSummary": "This study was a single-center,open-label,randomized,dose-exploring prospective study.Patients with granulocytotic aplastic anemia who received cytokine treatment with PEG-rhG-CSF or rhG-CSF were enrolled.Clinical demographic data,disease characteristics of aplastic anemia,clinical diagnosis and treatment,laboratory data and adverse events were collected to explore the dose and safety of PEG-rhG-CSF and rhG-CSF in patients with severe aplastic anemia.",
//           "detailedDescription": "This study was a single-center,open-label,randomized,dose-exploring prospective study.Patients with granulocytotic aplastic anemia who received cytokine treatment with PEG-rhG-CSF or rhG-CSF were enrolled.Clinical demographic data,disease characteristics of aplastic anemia,clinical diagnosis and treatment,laboratory data and adverse events were collected to explore the dose and safety of PEG-rhG-CSF and rhG-CSF in patients with severe aplastic anemia.Research objectives: To explore the reasonable injection frequency of long-acting PEG-rhG-CSF in the adjuvant treatment of aplastic anemia patients with granulocytosis through a single center prospective clinical study.Disease classification of aplastic anemia: a total of 45 cases of SAA/VSAA with ANC\\<0.5109/L were stratified and randomized into three groups according to the radio of 1:1:1(15 cases in each group).PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected;PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected;RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.Dose/protocol adjustment: after monitoring ANC\\>0.5109/L,the drug was stopped,and then ANC\\<0.5109/L was temporarily supplemented with one dose of the original group of drugs."
//         },
//         "conditionsModule": {
//           "conditions": [
//             "Severe Aplastic Anemia"
//           ],
//           "keywords": [
//             "G-CSF"
//           ]
//         },
//         "designModule": {
//           "studyType": "INTERVENTIONAL",
//           "phases": [
//             "NA"
//           ],
//           "designInfo": {
//             "allocation": "RANDOMIZED",
//             "interventionModel": "PARALLEL",
//             "primaryPurpose": "TREATMENT",
//             "maskingInfo": {
//               "masking": "NONE"
//             }
//           },
//           "enrollmentInfo": {
//             "count": 45,
//             "type": "ESTIMATED"
//           }
//         },
//         "armsInterventionsModule": {
//           "armGroups": [
//             {
//               "label": "PEG-rhG-CSF group A",
//               "type": "EXPERIMENTAL",
//               "description": "PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected,after monitoring ANC\\>0.5109/L,the drug was stopped,and then ANC\\<0.5109/L was temporarily supplemented with one dose of the same drug.",
//               "interventionNames": [
//                 "Drug: PEG-rhG-CSF"
//               ]
//             },
//             {
//               "label": "PEG-rhG-CSF group B",
//               "type": "EXPERIMENTAL",
//               "description": "PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected,after monitoring ANC\\>0.5109/L,the drug was stopped,and then ANC\\<0.5109/L was temporarily supplemented with one dose of the same drug.",
//               "interventionNames": [
//                 "Drug: PEG-rhG-CSF"
//               ]
//             },
//             {
//               "label": "rhG-CSF group(short-acting )",
//               "type": "EXPERIMENTAL",
//               "description": "rhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.After monitoring ANC\\>0.5109/L,the drug was stopped,and then ANC\\<0.5109/L was temporarily supplemented with one dose of the same drug.",
//               "interventionNames": [
//                 "Drug: PEG-rhG-CSF"
//               ]
//             }
//           ],
//           "interventions": [
//             {
//               "type": "DRUG",
//               "name": "PEG-rhG-CSF",
//               "description": "PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.",
//               "armGroupLabels": [
//                 "PEG-rhG-CSF group A",
//                 "PEG-rhG-CSF group B",
//                 "rhG-CSF group(short-acting )"
//               ],
//               "otherNames": [
//                 "rhG-CSF"
//               ]
//             }
//           ]
//         },
//         "outcomesModule": {
//           "primaryOutcomes": [
//             {
//               "measure": "total number of effective (ANC>0.5109/L) days",
//               "description": "total number of effective (ANC\\>0.5109/L) days during 2 weeks of treatment(casesdays).",
//               "timeFrame": "2 weeks"
//             }
//           ]
//         },
//         "eligibilityModule": {
//           "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18-70 years old, male or female, or weight50kg.\n2. Patients with severe or very severe aplastic anemia of absolute neutrophil value\\< 0.5109/L\n3. ECOG score  2 points.\n4. Normal renal function.\n\nExclusion Criteria:\n\n1. Patients with clonal chromosomal abnormalities.\n2. Patients with previous malignant tumors.\n3. Patients with severe or uncontrolled infectious diseases and /or bleeding.\n4. Patients with AIDS or syphilis positive.\n5. Severe organ dysfunction.\n6. Patients used GM/G-CSF,PEG-rhG-CSF,interleukin-11 within 2 weeks before admission.\n7. Allergic to G-CSF or PEG-rhG-CSF related components.\n8. Participated in other clinical trials within 6 months.",
//           "healthyVolunteers": false,
//           "sex": "ALL",
//           "minimumAge": "18 Years",
//           "maximumAge": "70 Years",
//           "stdAges": [
//             "ADULT",
//             "OLDER_ADULT"
//           ]
//         },
//         "contactsLocationsModule": {
//           "centralContacts": [
//             {
//               "name": "Fengkui Zhang, Doctor",
//               "role": "CONTACT",
//               "phone": "+862223909229",
//               "email": "fkzhang@ihcams.ac.cn"
//             },
//             {
//               "name": "Huihui Fan, Doctor",
//               "role": "CONTACT",
//               "phone": "+862223909223",
//               "email": "fanhuihui@ihcams.ac.cn"
//             }
//           ],
//           "overallOfficials": [
//             {
//               "name": "Liping Jing, Doctor",
//               "affiliation": "Institute of Hematology  Blood Diseases HospitalChinese Academy of Medical Sciences",
//               "role": "STUDY_DIRECTOR"
//             }
//           ],
//           "locations": [
//             {
//               "facility": "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences",
//               "status": "RECRUITING",
//               "city": "Tianjin",
//               "state": "Tianjin",
//               "zip": "300020",
//               "country": "China",
//               "contacts": [
//                 {
//                   "name": "Fengkui Zhang, Doctor",
//                   "role": "CONTACT",
//                   "phone": "8602223909229",
//                   "email": "fkzhang@ihcams.ac.cn"
//                 },
//                 {
//                   "name": "Huihui Fan, Doctor",
//                   "role": "CONTACT",
//                   "phone": "8602223909223",
//                   "email": "fanhuihui@ihcams.ac.cn"
//                 }
//               ],
//               "geoPoint": {
//                 "lat": 39.14222,
//                 "lon": 117.17667
//               }
//             }
//           ]
//         },
//         "referencesModule": {
//           "references": [
//             {
//               "pmid": "21233311",
//               "type": "RESULT",
//               "citation": "Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Hochsmann B, Barrois A, Champion K, Passweg JR. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011 Apr 28;117(17):4434-41. doi: 10.1182/blood-2010-08-304071. Epub 2011 Jan 13."
//             }
//           ]
//         },
//         "ipdSharingStatementModule": {
//           "ipdSharing": "YES",
//           "description": "We can share the plan after completing the experiment",
//           "infoTypes": [
//             "STUDY_PROTOCOL",
//             "ICF",
//             "CSR"
//           ],
//           "timeFrame": "Follow-up and publication of the paper are planned for December 2025",
//           "accessCriteria": "After the paper is written and published"
//         }
//       },
//       "derivedSection": {
//         "miscInfoModule": {
//           "versionHolder": "2024-12-19"
//         },
//         "conditionBrowseModule": {
//           "meshes": [
//             {
//               "id": "D000740",
//               "term": "Anemia"
//             },
//             {
//               "id": "D000741",
//               "term": "Anemia, Aplastic"
//             }
//           ],
//           "ancestors": [
//             {
//               "id": "D006402",
//               "term": "Hematologic Diseases"
//             },
//             {
//               "id": "D000080983",
//               "term": "Bone Marrow Failure Disorders"
//             },
//             {
//               "id": "D001855",
//               "term": "Bone Marrow Diseases"
//             }
//           ],
//           "browseLeaves": [
//             {
//               "id": "M4070",
//               "name": "Anemia",
//               "asFound": "Anemia",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M4071",
//               "name": "Anemia, Aplastic",
//               "asFound": "Aplastic Anemia",
//               "relevance": "HIGH"
//             },
//             {
//               "id": "M9490",
//               "name": "Hematologic Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M2241",
//               "name": "Bone Marrow Failure Disorders",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M13118",
//               "name": "Pancytopenia",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M5134",
//               "name": "Bone Marrow Diseases",
//               "relevance": "LOW"
//             },
//             {
//               "id": "T460",
//               "name": "Aplastic Anemia",
//               "asFound": "Aplastic Anemia",
//               "relevance": "HIGH"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "BC15",
//               "name": "Blood and Lymph Conditions"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Conditions"
//             },
//             {
//               "abbrev": "Rare",
//               "name": "Rare Diseases"
//             }
//           ]
//         },
//         "interventionBrowseModule": {
//           "browseLeaves": [
//             {
//               "id": "M17201",
//               "name": "Ubiquinone",
//               "relevance": "LOW"
//             },
//             {
//               "id": "M271049",
//               "name": "Coenzyme Q10",
//               "relevance": "LOW"
//             },
//             {
//               "id": "T383",
//               "name": "Coenzyme Q10",
//               "relevance": "LOW"
//             }
//           ],
//           "browseBranches": [
//             {
//               "abbrev": "Micro",
//               "name": "Micronutrients"
//             },
//             {
//               "abbrev": "All",
//               "name": "All Drugs and Chemicals"
//             },
//             {
//               "abbrev": "Ot",
//               "name": "Other Dietary Supplements"
//             }
//           ]
//         }
//       },
//       "hasResults": false
//     }
//   ],
//   "nextPageToken": "KV165pePlfg"
// }
